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ABSTRACT: A series of N-substituted (2-phenylcycloprop-
yl)methylamines were designed and synthesized, with the aim
of finding serotonin 2C (5-HT2C)-selective agonists with a
preference for Gq signaling. A number of these compounds
exhibit 5-HT2C selectivity with a preference for Gq-mediated
signaling compared with β-arrestin recruitment. Furthermore,
the N-methyl compound (+)-15a, which displayed an EC50 of 23 nM in the calcium flux assay while showing no β-arrestin
recruitment activity, is the most functionally selective 5-HT2C agonist reported to date. The N-benzyl compound (+)-19, which
showed an EC50 of 24 nM at the 5-HT2C receptor, is fully selective over the 5-HT2B receptor. In an amphetamine-induced
hyperactivity model, compound (+)-19 showed significant antipsychotic-drug-like activity. These novel compounds shed light on
the role of functional selectivity at the 5-HT2C receptor with respect to antipsychotic activity.
■ INTRODUCTION
The serotonin 2C (5-HT2C) receptor, a serotonin (5-HT, 1;
Figure 1), G-protein-coupled receptor (GPCR), has been iden-
tified as a promising drug target for obesity and other cen-
tral nervous system (CNS) disorders, such as schizophrenia
and drug addiction.1−6 The 5-HT2C receptor shares approx-
imately 50% homology similarity with the other two 5-HT2
subtypes, namely, the 5-HT2A and 5-HT2B receptors, where
agonists respectively mediate hallucinogenic activity7 and
cardiac valvulopathy.8,9
Furthermore, the classical understanding of GPCR signaling
has undergone important changes in recent years with the
recognition of the phenomenon of “functional selectivity”,
namely, the ability of a specific agonist to differentially mediate
multiple receptor signaling events (i.e., Gq-linked calcium flux
vs β-arrestin recruitment in the case of 5-HT2C receptors).
10
β-Arrestin was named after its initially discovered ability to
arrest (turn off) GPCR signaling, and is an important down-
stream signaling and regulatory factor. β-Arrestin recruitment is
responsible for desensitization, internalization, and eventual
degradation of GPCRs.11 It has furthermore been demon-
strated that the β-arrestin-mediated signaling pathway functions
can provide signaling independent of G-protein pathways.12
Thus, a GPCR agonist that has minimal capability to activate
the β-arrestin signaling pathway could display long-term
efficacy in regard to tolerance mediated by receptor desensitiza-
tion and downregulation. Recently, biased GPCR ligands have
been suggested to offer great therapeutic benefits as new-
generation drugs with enhanced efficacy and functional selec-
tivity, resulting in reduced side effects.13,14
Thus, to develop 5-HT2C agonists as potential antipsychotic
medications, it is essential to explore ligands that are both
G-protein-biased and highly selective over 5-HT2B and 5-HT2A.
Most importantly, the high selectivity for 5-HT2C over 5-HT2B
has emerged as paramount due to the fact that chronic 5-HT2B
agonism leads to irreversible cardiac valvulopathy, as illustrated
by the withdrawal of fenfluramine and pergolide and the restric-
tion of sales of cabergoline owing to their off-target activities at
the 5-HT2B receptor.
9 To date, a number of selective 5-HT2C
ligands have been disclosed (Figure 1). In particular, lorcaserin
(2) was approved by the FDA for the treatment of obesity in
2012. It shows excellent 5-HT2C agonist activity (EC50 = 9 nM,
Emax = 99%), but only moderate (100-fold) selectivity over
5-HT2B (EC50 = 943 ± 90 nM, Emax = 100%), which is relevant
to understanding the higher incidence of cardiac valve disorders
compared to placebo in clinical trails.15 Vabicaserin (3) with
partial agonism (Emax = 50%, EC50 = 12 or 102 nM, depending
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on the receptor expression level) at the 5-HT2B receptor has
failed to achieve its primary end points in clinical trails,
although a proof-of-concept has been achieved for the use of
5-HT2C agonists in treating schizophrenia.
16,17 The pyrimido-
[3,4-d]azepine PF-4479745 (5), a hybrid of lorcaserin and
CP-809101 (4),18 displays high potency (EC50 = 10 nM) and
moderate efficacy (Emax = 67%) at 5-HT2C while possessing no
measurable agonism at either the 5-HT2A or 5-HT2B receptor.
19
The pyrido[3,4-d]azepine PF-04781340 (6) is a potent 5-HT2C
ligand (EC50 = 9 nM, Emax = 99%), with about 160-fold selec-
tivity over 5-HT2B.
20 Both compounds 5 and 6 were reported
to have excellent ADME properties commensurate with an
orally bioavailable and CNS penetrant profile. However, to the
best of our knowledge, few biased 5-HT2C agonists have been
reported to date.21
In our prior work, tranylcypromine was identified as a hit
compound in an initial high-throughput screening (HTS) assay
using a library containing 800 compounds. We developed our
first-generation potent 5-HT2C agonists by homologation of the
side chain of tranylcypromine to (2-phenylcyclopropyl)meth-
ylamine (2-PCPMA).22 Subsequent structure−activity relation-
ship (SAR) studies indicated that a 2-alkoxy substituent is a
beneficial functional group for maintaining potency and
selectivity (Figure 2). Further fine-tuning of the 2-alkoxy and
the halogen substituents led to the identification of 11 and
12,23,24 which showed excellent pharmacological profiles with
regard to 5-HT2C potency and selectivity over 5-HT2A and
5-HT2B. In addition, compounds 11 and 12 showed only weak
β-arrestin recruitment efficacy (Emax = 23% and 26%, respectively;
unpublished data) similar to that of a series of structurally
similar benzofuran-based compounds reported recently.21
The achievement of optimal brain exposure, which is a
critical and challenging task in CNS drug discovery, requires a
more restrictive selection of physicochemical properties
compared to orally active, peripheral drugs (rule of 5).25−27
Due to the relatively low molecular weights (MWs) of the
(2-phenylcyclopropyl)methylamines (for example, MW < 230
for 11 and 12), the addition of halogen atoms to the phenyl
ring has previously been demonstrated to improve brain pene-
trance.23,24 To further optimize druglike properties, alkylation
at the basic primary amino group of the 2-PCPMA scaffold was
envisioned to provide opportunities for additional noncovalent
interactions with the 5-HT2C receptor while also increasing
the ligands’ lipophilicity. In earlier studies, we found that
N-methylation of [2-(2-methoxyphenyl)cyclopropyl]methylamine
(8; cLogP = 1.59, LogBB = −0.04) gave a fully Gq-biased 5-HT2C
agonist with good potency (EC50 = 23 nM, Emax = 71%, cLogP =
2.07, LogBB = 0.26), while N-methylation of our first-genera-
tion (2-phenylcyclopropyl)methylamine (7) led to a dramatic
loss in activity.22 Moreover, it has been reported that N-ben-
zylation of phenethylamines and 5-methoxytryptamines leads
to improved agonism at 5-HT2 receptors.
28,29 Given that the
additional N-substitution could improve the physicochemical
properties in terms of further enhancing brain penetration, a
new series of N-substituted [2-(2-alkoxyphenyl)cyclopropyl]-
methylamines (Figure 2) were developed and evaluated for
their potency and bias profiles in continuation of our previous
SAR studies, along with behavioral tests and in vitro ADMET
Figure 1. Selected 5-HT2C agonists.
Figure 2. Selected 5-HT2C agonists based on the (2-phenylcyclopropyl)methylamine scaffold and new N-substituted derivatives.
studies of a promising 5-HT2C receptor agonist which showed
no activity at the 5-HT2B receptor.
■ RESULTS AND DISCUSSION
Chemistry. N-Monomethylation of compounds 8, 11, and
12 was carried out starting from Boc-protected [2-(2-alkoxy-
phenyl)cyclopropyl]methylamines (−)-13a−c reported previ-
ously by our group as synthetic intermediates.23 As shown in
Scheme 1, introduction of an N-methyl group with NaH and
iodomethane followed by deprotection under acidic condition
(2 M HCl/Et2O) afforded the N-methylamines (+)-15a−c.
Since the N-methylamine (+)-15a possessing a methoxy group
at the 2-position of the phenyl ring maintained potency at
5-HT2C, the present work was focused on N-substituted analogues
of compound 8.
The synthesis of these compounds was accomplished from
the cyclopropane-bearing aldehyde D and primary amine G
(Scheme 2)30 by reductive amination or N-substitution reac-
tions (Scheme 3). For example, the N-alkyl derivatives 16−18
and N-arylmethyl/heteroarylmethyl derivatives 19−22, 26−32,
34, and 35 were synthesized starting from the aldehyde D
and amines by treatment with NaBH4 or NaBH(OAc)3. The
tertiary amine 23 was prepared from the phenol 22 using a
Mitsunobu reaction with 2-fluoroethanol. The N-arylmethyl/
heteroarylmethyl derivatives 24, 33, and 36−39 were synthe-
sized from the primary amine G and appropriate aldehydes
following the same approach, while the derivative 24 was
Scheme 1. Synthesis of N-Methyl Analogues (+)-15a−ca
aReagents and conditions: (a) MeI, NaH, THF, rt; (b) 2 M HCl/Et2O, rt.
Scheme 2. Synthesis of Intermediates D and Ga
aReagents and conditions: (a) Ph3PCHC(O)N(OMe)Me, CH2Cl2, rt; (b) Me3S+(O)I−, NaH, DMSO, rt; (c) DIBAL-H, THF, −78 °C;
(d) NaBH4, MeOH, 0 °C to rt; (e) phthalimide, PPh3, DEAD, THF, rt; (f) N2H4·H2O, EtOH, reflux.
Scheme 3. Synthesis of Target Compounds 16−39a
aReagents and conditions: (a) RNH2, NaBH4, MeOH; (b) 2-methoxy-N-methylbenzylamine, NaBH4, MeOH; (c) 2 M HCl/Et2O, rt; (d) Ph3P,
DEAD, 2-fluoroethanol, THF; (e) ArCH2OTs, K2CO3, CH3CN for 24; ArCHO, NaBH(OAc)3, DCE for 33 and 37−39; ArCHO, NaBH4, MeOH
for 36; (f) NaOH, H2O2, MeOH.
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prepared from the intermediate tosylate 24b (Scheme 4) via a
nucleophile substitution reaction. Hydrolysis of 24 under basic
conditions (NaOH/H2O2) smoothly afforded the amide 25.
The intermediate cyclopropylamine 30b for the synthesis of
compound 30 was obtained from 2-methoxybenzonitrile (30a)
using EtMgBr and Ti(OiPr)4, followed by treatment with a
Lewis acid (BF3·Et2O) (Scheme 4).
31 The intermediate thio-
pheneylmethanamines 34e and 35e required for the synthesis
of compounds 34 and 35 were prepared in four steps as
illustrated in Scheme 5. The commercial thiophenes 34a and
35a were brominated with NBS followed by replacement of
bromide with tritylamine to provide 34c and 35c in high yield.
The bromides 34c and 35c were reacted with CH3ONa/CuBr
to afford 34d and 35d,32 followed by the removal of the Trt
group under acidic conditions to give 34e and 35e as acetic acid
salts (Scheme 5).
Unless otherwise noted, the N-substituted derivatives were
tested as racemic mixtures. The N-benzyl derivatives of (+)-11
and (+)-12, namely, 40 and 41, respectively, were directly
prepared from the enantiomers (+)-(S,S)-11 and (+)-(S,S)-12
via reductive alkylation with 2-methoxybenzaldehyde, while
the pure (−)- and (+)-isomers of 19−21, 26, 27, and 32
were obtained by preparative HPLC on a chiral stationary phase
(Scheme 6). Compounds 40 and 41 were found to show the
same sign of optical rotation as their parent compounds (+)-11
and (+)-12. Moreover, our finding that the (+)-enantiomers of
all new N-arylmethyl/thiopheneylmethyl compounds are more
potent than their (−)-enantiomers is consistent with that pre-
viously observed for similar scaffolds.22−24 Thus, the absolute
configuration of the (+)-enantiomers was assigned as 1S,2S and
that of the (−)-enantiomers as 1R,2R.
In Vitro Pharmacology. Activity at 5-HT2 Receptors.
Preliminary studies demonstrated that (2-phenylcyclopropyl)-
methylamines with the phenyl ring bearing 2-alkoxy and
5-fluoro substituents provided excellent 5-HT2C potency and
selectivity over 5-HT2A and 5-HT2B receptors. Moreover, the
initial N-methylation of [2-(2-methoxyphenyl)cyclopropyl]-
methylamine (8) maintained potency at 5-HT2C (compound
(+)-15a: EC50 = 23 nM, Emax = 71%, Table 1), which was not
the case with the best ligands 11 and 12 (resulting in com-
pounds (+)-15b and (+)-15c). Further binding studies showed
that (+)-15a had a high affinity for 5-HT2C (Ki = 81 nM; see
Supporting Information Table S3). Thus, the parent compound
8 was taken as a lead to develop N-substituted derivatives.
Physicochemical properties such as cLogP and LogBB were
calculated to predict the blood−brain barrier (BBB) perme-
ability.
Substitution with larger alkyl groups, such as cyclopropyl
(compound 16) and cyclopropylmethyl (compound 17), led to
decreased potency at 5-HT2C (EC50 > 300 nM; Table 1).
However, in view of the lack of activity for the cyclopro-
pylmethyl derivative 17, it was intriguing that the even bulkier
cyclohexylmethyl derivative 18 showed moderate potency
(EC50 = 95 nM) and superior selectivity over 5-HT2B and
5-HT2A, but with extremely low efficacy (Emax = 15%). We
therefore saw an opportunity for the introduction of an
aromatic ring (Table 1), which could possibly engage in a π−π
stacking interaction with the receptor.
Furthermore, Nichols et al. have demonstrated that N-(2-
methoxybenzyl)-substituted 2, 5-dimethoxyphenethylamines
exhibited enhanced agonism at 5-HT2 receptors.
28,29 We there-
fore first prepared the N-(2-methoxybenzyl) analogue 19. The
compound (+)-19 proved to have high potency at 5-HT2C
(EC50 = 24 nM, Emax = 92%) and full selectivity against 5-HT2B.
In addition, it was hypothesized that a hydrogen bond acceptor
(HBA) at the ortho position of the benzyl moiety was beneficial
to improve the potency of N-benzylated 2,5-dimethoxyphene-
thylamines.29 Movement of the o-methoxy group to the meta
Scheme 4. Synthesis of Intermediates 24b and 30b for Analogues 24 and 30a
aReagents and conditions: (a) (i) NaBH4, MeOH; (ii) TsCl, TEA, DCM; (b) (i) EtMgBr, Ti(O
iPr)4, Et2O, −78 °C; (ii) BF3·Et2O, Et2O.
Scheme 5. Synthesis of Intermediates 34e and 35e for Analogues 34 and 35a
aReagents and conditions: (a) NBS, AIBN, CCl4, 60 °C; (b) TrtNH2, DCM, rt; (c) CH3ONa, CH3OH, CuBr, 100 °C; (d) AcOH, 50 °C.
Scheme 6. Preparation of Enantiomers 19−21, 26, 27, 32,
40, and 41a
aReagents and conditions: (a) 2-methoxybenzaldehyde, NaBH4,
MeOH; (b) chiral preparative HPLC separation; (c) 2 M HCl/
Et2O, rt.
Table 1. Functional Activity and Selectivity of N-Substituted Derivatives 15a−c and 16−41 at 5-HT2 Receptors in the Calcium
Flux Assaya
Table 1. continued
aAll new compounds were tested as HCl salts except compound 36, which was tested as the free base. Pharmacological data were acquired with
recombinant, stably expressed human 5-HT receptors in the HEK-293 cell line, using a fluorescence imaging plate reader (FLIPR) assay. pEC50 and
Emax values are shown as the mean ± SEM (n = 3). EC50 values were calculated from averaged pEC50 values. “NA” indicates no activity up to 10 μM.
“−” indicates structures of 5-HT and lorcaserin are not shown. cLogP and LogBB values were calculated for the free bases using the ACD Percepta
program.
and para positions as in compounds (+)-20 and (+)-21, respec-
tively, led to decreased potency (EC50 = 231 and 1200 nM).
Furthermore, substituents with different electronic and steric
properties acting as HBA groups at the 2-position of the benzyl
group were investigated. The phenol 22 gave modest activity
at 5-HT2C (EC50 = 304 nM, Emax = 63%) but poor selectivity
(0.25-fold) against 5-HT2A, although it showed full selectivity
over 5-HT2B. The slightly bulkier 2-fluoroethyl
33 derivative 23
showed good potency at 5-HT2C (EC50 = 28 nM), but only
2-fold selectivity against 5-HT2B (EC50 = 56 nM). The cyano and
carbamoyl derivatives 24 and 25 displayed attenuated activity
(EC50 > 200 nM, Emax < 35%). Moreover, introduction of other
electron-withdrawing groups (EWGs) such as F (compound
(+)-26) and Cl (compound (+)-27) resulted in significant loss
of potency at 5-HT2C (EC50 > 500 nM), which suggested that
an EWG attached to the phenyl ring of the benzyl group was
disadvantageous for 5-HT2C activity. Additional N-methylation
of the benzylamine moiety as in analogue 28 resulted in a
15-fold reduction of 5-HT2C potency (EC50 = 670 nM for the
racemate) compared to that of the parent compound (+)-19.
Additional substitution at the benzylic position of the 2-meth-
oxybenzyl moiety with methyl and ethylene groups led to the
sterically hindered analogues 29 and 30, respectively, with a
predicted increase in BBB penetration based on the calculated
LogBB values. Their potency at 5-HT2C was, however, reduced.
Moreover, homologation of the N-(2-methoxybenzyl) moiety
as in compound 31 led to reduced potency at 5-HT2C (EC50 =
615 nM) and increased potency at 5-HT2B (EC50 = 96 nM).
To explore further structural diversity, N-heteroarylmethyl
derivatives with altered electron densities in the aromatic ring
that might result in different pharmacokinetic properties were
investigated as depicted in Table 1. The isosteric thiophene
derivative (+)-32 showed 120 nM potency at 5-HT2C and
full selectivity against 5-HT2B. In line with the N-benzyl
derivatives above, (+)-32 was more potent at 5-HT2C than its
(−)-enantiomer (EC50 = 308 nM). Upon introduction of an
additional methoxy group at the 3-position of the thiophene
ring (compound 33), a 2-fold increased potency at 5-HT2C
(EC50 = 121 nM for the racemate) and good selectivity against
5-HT2B were obtained. The regioisomers 34 and 35 displayed
weaker potency at 5-HT2C. In contrast, the electron-deficient
pyridine derivative 36 was less potent at 5-HT2C (EC50 = 433 nM)
compared to (+)-32. Moreover, several benzene-fused
heterocyclic derivatives (37−39) with various heteroatoms
(N and S) at the 2-position of the benzene ring were also inves-
tigated. Intriguingly, in contrast with the modest potency at
5-HT2C of the benzo[b]thiophene derivative 37 (EC50 = 777 nM)
and quinoline derivative 39 (EC50 = 530 nM), the indole
derivative 38 was entirely inactive at 5-HT2C, which possibly
resulted from the absence of a hydrogen bond acceptor at the
ortho position of the aryl ring.
In an effort to discover potent and selective 5-HT2C agonists
in a series of N-substituted [2-(2-methoxyphenyl)cyclopropyl]-
methylamines, the N-(2-methoxybenzyl) derivative (+)-19 has
been established as the best ligand in terms of selectivity for
5-HT2C. Introduction of the N-(2-methoxybenzyl) group onto
the previously reported 5-HT2C-selective ligands 11 and 12 also
gave very high 5-HT2C potency (40, EC50 = 9.2 nM, Emax =
97%; 41, EC50 = 2.4 nM, Emax = 93%), but poor selectivity
against 5-HT2B (40, EC50 = 113 nM; 41, EC50 = 24 nM) and
5-HT2A (40, EC50 = 28 nM; 41, EC50 = 24 nM). Furthermore,
to identify potential off-target activity, compound (+)-19 was
profiled against a panel of serotonin receptors, dopamine
receptors, monoamine transporters, and other selected CNS
targets (see Supporting Information Table S2). Compound
(+)-19 showed good selectivity with a much higher binding
affinity for 5-HT2C (Ki = 78 nM) than 5-HT2B (Ki = 411 nM)
and 5-HT2A (Ki = 492 nM). None of the other screened targets
were found to display any significant off-target affinity for
compound (+)-19. Taken together, compound (+)-19 repre-
sents a good candidate for further studies in terms of both its
5-HT2C and selectivity.
5-HT2C Functional Selectivity. Recently, we have discovered
benzofuran-based compounds as functionally selective 5-HT2C
agonists with weak β-arrestin recruitment activities.21 How-
ever, no fully biased 5-HT2C agonist has been disclosed to
date. The functional selectivity of the above 5-HT2C-selective
N-substituted (2-phenylcyclopropyl)methylamines was inves-
tigated and compared to that of lorcaserin and 5-HT. β-Arrestin
recruitment activity was tested using reported methods21,34 in
parallel with a Gq-mediated calcium flux assay using the same
drug dilutions. The relative activities (log(Emax/EC50)) were
calculated to account for partial agonist differences. As shown
in Table 2 and Figure 3, compounds (+)-15a and (+)-32
showed no β-arrestin recruitment activity, which indicates that
these compounds exclusively signal via Gq-mediated calcium
flux. The N-(2-methoxybenzyl) derivative (−)-19 also dis-
played a preference for Gq-mediated calcium flux with weak
potency (>1 μM) for β-arrestin recruitment activity, whereas
its (+)-enantiomer showed stronger potency for β-arrestin
recruitment (EC50 = 70 nM) albeit with much reduced efficacy
(Emax = 43%) compared to the reference ligand, lorcaserin
(EC50 = 40 nM, Emax = 97%). The N-(2-methoxybenzyl) deriv-
atives of 11 and 12, namely, (+)-40 and (+)-41, respectively,
Table 2. Functional Selectivity for 5-HT2C-Selective Agonists
a
Gq calcium flux β-arrestin-2
compd pEC50 (EC50, nM) Emax (%) log(Emax/EC50) pEC50 (EC50, nM) Emax (%) log(Emax/EC50)
5-HT 9.74 ± 0.02 (0.18) 100 ± 0.9 9.85 7.82 ± 0.03 (15) 100 ± 1.0 7.82
lorcaserin 8.68 ± 0.04 (2.1) 101 ± 1.4 8.68 7.40 ± 0.05 (40) 97 ± 2.1 7.38
(+)-15a 7.64 ± 0.05 (23) 71 ± 1.4 7.49 NA NA
(+)-19 7.62 ± 0.04 (24) 92 ± 1.3 7.58 7.16 ± 0.04 (70) 43 ± 0.9 6.79
(−)-19 6.99 ± 0.05 (103) 104 ± 2.1 7.00 >1000 ND
(+)-32 6.92 ± 0.06 (120) 60 ± 0.7 6.70 NA NA
(+)-40 8.04 ± 0.04 (9.2) 97 ± 1.3 8.02 7.64 ± 0.05 (22.7) 56 ± 1.0 7.39
(+)-41 8.62 ± 0.03 (2.4) 93 ± 1.1 8.59 7.96 ± 0.05 (11) 54 ± 1.0 7.69
aData were acquired with the human 5-HT2C-INI receptor isoform measuring the Gq calcium flux (FLIPR) and β-arrestin-2 recruitment (Tango).
Emax values are shown as the mean ± SEM (n = 3), and assays were conducted in parallel with the same drug dilutions. “NA” indicates no activity up
to 10 μM. “ND” indicates not determined because of no saturable Emax.
had a preference for Gq signaling driven mainly by their weaker
β-arrestin recruitment efficacy (Emax = 56% and 54%, respec-
tively) compared to lorcaserin (Emax = 97%).
Evaluation in Animal Models of Antipsychotic-Drug-
like Activity. In vitro pharmacology profiles identified the
N-(2-methoxybenzyl) compound (+)-19 as the most potent
5-HT2C agonist (EC50 = 24 nM, Emax = 92%) with full selec-
tivity over 5-HT2B in the present series of compounds. As the
absence of 5-HT2B agonism is necessary to avoid potential
cardiovascular side effects, compound (+)-19 was selected for
further in vivo studies in the amphetamine (AMPH)-induced
and phencyclidine (PCP)-induced hyperactivity models (details
of the behavioral studies are provided in the Experimental
Section), which are both well-recognized models to evaluate
the possible antipsychotic activities of compounds.
AMPH-Induced Hyperactivity Model. In this model, adult
male C57BL/6J mice were administered saline (vehicle),
lorcaserin (as the positive control, 3 mg/kg), or the test
compound (+)-19 (10 and 20 mg/kg), and locomotor activity
was monitored for 15 min (baseline). As shown in Figure 4A,
lorcaserin decreased baseline locomotion, while the compound
(+)-19 (10 and 20 mg/kg) had no effect. Next the mice were
given saline or amphetamine (3 mg/kg), and the activity was
measured for an additional 90 min. The results showed that
lorcaserin reduced amphetamine-induced hyperactivity consis-
tent with other 5-HT2C agonists,
35,36 whereas responses to
10 and 20 mg/kg (+)-19 were differentiated by dose (Figure 4A,B).
Although the low dose (10 mg/kg) of (+)-19 had no significant
effect, the higher dose (20 mg/kg) decreased the hyper-
locomotion such that its effects were similar to those of
lorcaserin. Thus, compound (+)-19 (20 mg/kg) showed an
antipsychotic action by blocking amphetamine-induced hyper-
activity with no effect on spontaneous motor activity.
Phencyclidine (PCP)-Induced Hyperactivity Model. In
contrast to amphetamine-induced hyperactivity, lorcaserin
showed a tendency to suppress PCP-induced hyperactivity at
the beginning of the test session, but there was no overall
reduction in activity that was statistically significant. While
the low dose (10 mg/kg) of (+)-19 increased locomotion, the
higher dose (20 mg/kg) had no effect on PCP-induced hyper-
locomotion (Figure 4C,D). In general, it has been demon-
strated that 5-HT2C agonists decrease PCP-induced hyper-
activity.37,38 The locomotion enhancement observed with
the lower dose of (+)-19 could result from other off-target
effects on PCP. For example, from our in vitro ADMET results
(Table 3), (+)-19 exhibits strong inhibition (85.6%, Table 3) of
human cytochrome P450 (CYP) 3A4 (in the mouse mainly its
highly homologous 3A11),39 which is the same enzyme that has
been reported to metabolize PCP.40 Alternatively, the 5-HT2A
agonism of (+)-19 (EC50 = 139 nM, Emax = 63%, Table 1)
might also explain its effect on PCP-induced locomotor activity.
The 5-HT2A/2C agonist DOI (5-HT2A, EC50 = 57 nM, Emax =
46%; 5-HT2C, EC50 = 178 nM, Emax = 90%)
41 has been shown
to potentiate the locomotor effects of PCP.42 These results
indicate that (+)-19 at doses of either 10 or 20 mg/kg does not
possess an antipsychotic-like profile in the PCP-induced loco-
motion model.
In summary, (+)-19 has superiority over lorcaserin on the
basis of its behavioral profile in decreasing amphetamine-
induced hyperactivity without having an effect on spontaneous
Figure 3. Profiling of 5-HT2C functional selectivity measuring Gq calcium flux (FLIPR, red) and β-arrestin-2 recruitment (Tango, blue). Data were
acquired with the human 5-HT2C-INI receptor isoform. Emax values are shown as the mean (n = 3), and assays were conducted in parallel with the
same drug dilutions.
activity. Further studies are required to determine the precise
mechanism of the enhancement of PCP using the lower dose
(+)-19.
ADMET Studies (in Vitro). Due to its efficacy in the
amphetamine-induced hyperactivity model, compound (+)-19
was evaluated for selected in vitro ADMET properties (Table 3)
to qualify it as a possible candidate for further development.
Compared with the structurally similar parent [2-(5-chloro-
phenyl)cyclopropyl]methylamines (+)-9 and (+)-10 previously
reported by us, the N-benzylated derivative (+)-19 displayed
higher human plasma protein binding (82%, (+)-19; 75%,
(+)-9; 57%, (+)-10)23 as a result of its enhanced lipophilicity,
as the cLogP is a highly correlated indicator that determines
protein binding properties. In the recombinant CYP inhibition
assay, (+)-19 showed low inhibition of CYP 1A2 and CYP 2C9
and relatively higher inhibition of CYP 2D6 and CYP 3A4 at
10 μM (>50%). Compound (+)-19 was found to have a
half-life of 43 min in the human hepatocyte stability assay, which
may be a consequence of the presence of the electron-rich
N-benzyl group.43 Moreover, moderate hERG inhibition
(IC50 = 1.4 μM) was detected.
■ CONCLUSIONS
New N-substituted (2-phenylcyclopropyl)methylamines have
been characterized as reasonably selective 5-HT2C receptor
agonists with novel patterns of functional selectivity. The
N-methyl compound (+)-15a, which displayed an EC50 of
23 nM at 5-HT2C with no β-arrestin recruitment activity, is the
first potent and at the same time fully Gq-biased 5-HT2C agonist
reported to date, while the N-benzyl compound (+)-19 with an
EC50 of 24 nM at 5-HT2C is fully selective over 5-HT2B. The
potency and lack of detectable arrestin recruitment of (+)-15a
make it a valuable chemical probe to better understand biased
5-HT2C signaling. Moreover, although (+)-19 had a relatively
short half-life in the hepatocyte stability assay, preliminary
in vivo studies in an amphetamine-induced hyperactivity model
indicate that (+)-19 shows potential antipsychotic effects.
Figure 4. Evaluation of compound (+)-19 in animal models of antipsychotic-drug-like activity. (A) Locomotor activity reflecting baseline responses
(0−15 min) and AMPH-induced hyperactivity with reductions by lorcaserin and (+)-19 (20−105 min). (B) Cumulative baseline locomotor
activities (0−15 min), AMPH-induced hyperactivities, and reductions by lorcaserin and (+)-19 (20−105 min): ∧, p < 0.05, compared to the Sal−Sal
group, baseline; *, p < 0.05 compared to Sal−AMPH, post-AMPH. (C) Locomotor activity reflecting baseline responses (0−15 min) and
PCP-induced hyperactivity with effects by lorcaserin and (+)-19 (20−75 min). (D) Cumulative baseline locomotor activities (0−15 min),
PCP-induced hyperactivities, and effects by lorcaserin and (+)-19 (20−75 min): ∧, p < 0.05, compared to the Sal−Sal group, baseline; *, p < 0.05
compared to Sal−PCP, post-PCP. N = 8−10 mice/group.
Table 3. In Vitro ADMET Data for Compound (+)-19
assay (+)-19 value
PPB at 10 μM (%) human 82.0
mouse 92.0









aThe CYP inhibition test was performed using human liver
microsomes. Phenacetin, tolbutamide, dextromethorphan, and mid-
azolam were used as test substrates for the 1A2, 2C9, 2D6, and 3A4
isoforms, respectively. bThe concentration of hepatocytes was 0.5 ×
106 cells/mL, and (+)-19 was tested at 1 μM. chERG inhibition was
tested on CHO cells using the automated patch-clamp method.
Further compound optimization to develop better druglike
analogues is in progress.
■ EXPERIMENTAL SECTION
General Procedures. All chemicals and solvents were purchased
from Sigma-Aldrich or Fisher Scientific and were used as obtained
without further purification. Microwave reactions were run in a
Biotage Initiator microwave reactor. Synthetic intermediates were
purified on 230−400 mesh silica gel using a Teledyne CombiFlash
Rf flash chromatograph.
1H and 13C NMR spectra were recorded on a
Bruker DPX-400 or AVANCE-400 spectrometer at 400 or 100 MHz,
respectively. NMR chemical shifts are reported in δ (ppm) using
residual solvent peaks as standards (CDCl3, 7.26 (H), 77.16 (C);
CD3OD, 3.31 (H), 49.00 (C)). Mass spectra were measured using an
LCMS−IT-TOF (Shimadzu) mass spectrometer in ESI mode. Pre-
parative HPLC purification of synthetic intermediates was performed
on a Shimadzu LC-8A instrument with an ACE 5AQ column (150 ×
21.2 mm, particle size 5 μm; eluent 8−100% MeOH (0.05% TFA)/
H2O (0.05% TFA) gradient, 30 min; flow rate 17 mL/min; UV
detection at 254 and 280 nm). Chiral separation of racemic inter-
mediates was conducted by preparative HPLC on a RegisPack (25 cm
× 21.1 mm, particle size 10 μm) or ChromegaChiral CCJ (25 cm ×
20 mm, particle size 10 μm) chiral column with 2-propanol (0.05%
diethylamine, DEA)/n-hexane (0.05% DEA) as the eluent. The purity
of all final compounds (greater than 95% in all cases) was determined
by analytical HPLC on an ACE 3AQ C18 column (150 × 4.6 mm,
particle size 3 μm; eluent MeOH (0.05% TFA)/H2O (0.05% TFA)
gradient, 25 min; flow rate 1.0 mL/min). Specific rotations were
recorded on a Rudolph Research Autopol IV automatic polarimeter.
The synthetic procedures, chiral separation methods, and character-
ization data of all intermediates can be found in the Supporting
Information. All intermediates subjected to chiral preparative HPLC
separation were prepared with an optical purity of >90% ee (deter-
mined by analytical HPLC using a RegisPack (25 cm × 4.6 mm,
10 μm) or ChromegaChiral CCJ (25 cm × 4.6 mm, 10 μm) chiral
column and 2-propanol (0.05% DEA)/n-hexane (0.05% DEA) as the
eluent.
General Method A: Preparation of HCl Salts 15a−c. The
N-Boc-amines 14a−c were dissolved in 2 M HCl(g) in diethyl ether
(5 equiv), and the resulting solutions were stirred at room temperature
for 24−48 h. The white solids formed were collected by filtration,
washed with diethyl ether, and dried under vacuum to give the HCl
salts as white solids.
General Method B: Preparation of HCl Salts 16−22, 26−32,
34, and 35 from the Intermediate Aldehyde D. The aldehyde D
was prepared according to the reported procedure.24 Aldehyde D
(1.0 equiv) and amines (1.2 equiv) were reacted under reductive
amination conditions (NaBH4 (1.5 equiv)/MeOH). The reaction
mixtures were quenched with water and extracted with DCM. The
organic phases were washed with brine, dried over sodium sulfate,
concentrated, and purified by preparative HPLC to give the trifluoro-
acetate salts. The salts were neutralized with aq NaHCO3, and the
resulting solutions were extracted with DCM. The organic layers were
dried over sodium sulfate and concentrated to provide the desired
compounds as free bases. For 19−21, 26−27, and 32, the obtained
racemic free bases were separated by chiral preparative HPLC to afford
their enantiomers (see the Supporting Information). The racemic or
enantiopure free bases were dissolved in 2 M HCl(g) in diethyl ether
(3 equiv), and the resulting solutions were stirred at room temperature
for 1−2 h. The white solids formed were collected by filtration, washed
with diethyl ether, and dried under vacuum to give the HCl salts as
white solids in high yields (80−95%).
General Method C: Preparation of HCl Salts 24, 25, 33, and
36−39 from the Intermediate Cyclopropylmethylamine G. The
cyclopropylmethylamine G was prepared according to the reported
procedure.24 The listed compounds were prepared from the cyclopro-
pylmethylamine G (1.0 equiv) and ArCHO (1.0 equiv) or ArCH2OTs
(1.0 equiv) via reductive amination (NaBH4 (1.5 equiv)/MeOH or
NaBH(OAc)3 (2.0 equiv)/DCE) or nucleophile substitution reactions
(base/CH3CN), respectively. The crude products were purified by
preparative LC and reacted with 2 M HCl/Et2O to afford the HCl salts
as white solids according to the similar procedure described for general
method B.
(+)-1-[(1S,2S)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl]-N-
methylmethanamine Hydrochloride (15a). The title compound
was obtained from the intermediate 14a (56 mg, 0.18 mmol)
employing general method A (40 mg, 90% yield): 1H NMR (CDCl3)
δ 9.61 (s, 2H), 6.88−6.82 (m, 1H), 6.76 (dd, J = 9.0, 4.6 Hz, 1H), 6.66
(dd, J = 9.3, 3.0 Hz, 1H), 3.85 (s, 3H), 3.10 (dd, J = 13.1, 7.1 Hz, 1H),
3.02 (dd, J = 13.0, 7.6 Hz, 1H), 2.75 (s, 3H), 2.25−2.07 (m, 1H),
1.52−1.37 (m, 1H), 1.21−1.09 (m, 2H); 13C NMR (CDCl3) δ 157.2
(d, J = 238.2 Hz), 154.5 (s), 130.6 (d, J = 7.4 Hz), 113.3 (d, J =
23.9 Hz), 113.1 (d, J = 22.5 Hz), 111.2 (d, J = 8.5 Hz), 56.2 (s), 52.9
(s), 32.1 (s), 17.8 (s), 16.9 (s), 13.0 (s); HRMS (ESI) calculated for
C12H17FNO ([M + H]




methylmethanamine Hydrochloride (15b). The title compound
was obtained from the intermediate 14b (188 mg, 0.56 mmol)
employing general method A (140 mg, 93% yield): 1H NMR (CDCl3)
δ 9.62 (s, 2H), 6.82 (td, J = 8.4, 3.0 Hz, 1H), 6.75 (dd, J = 8.9, 4.6 Hz,
1H), 6.65 (dd, J = 9.3, 3.0 Hz, 1H), 6.14−6.02 (m, 1H), 5.41 (dd, J =
17.2, 1.4 Hz, 1H), 5.30 (dd, J = 10.5, 1.4 Hz, 1H), 4.54 (d, J = 5.3 Hz,
2H), 3.21−3.06 (m, 1H), 3.05−2.92 (m, 1H), 2.73 (s, 3H), 2.25−2.17
(m, 1H), 1.53−1.41 (m, 1H), 1.15 (t, J = 7.1 Hz, 2H); 13C NMR
(CDCl3) δ 157.3 (d, J = 238.7 Hz), 153.4 (s), 133.4 (s), 131.0 (d, J =
7.3 Hz), 118.0 (s), 113.2 (d, J = 23.8 Hz), 113.1 (d, J = 22.6 Hz),
112.7 (d, J = 8.4 Hz), 69.9 (s), 52.8 (s), 32.2 (s), 17.9 (s), 17.0 (s),
13.0 (s); HRMS (ESI) calculated for C14H19FNO ([M + H]
+),
236.1445; found, 236.1408; [α]D
20 +20.3 (c 0.1, CHCl3).
(+)-1-[(1S,2S)-2-[5-Fluoro-2-(2-fluoroethoxy)phenyl]-
cyclopropyl]-N-methylmethanamine Hydrochloride (15c). The
title compound was obtained from the intermediate 14c (70 mg,
0.20 mmol) employing general method A (52 mg, 95% yield): 1H NMR
(CDCl3) δ 9.53 (s, 2H), 6.86 (td, J = 8.5, 2.7 Hz, 1H), 6.77 (dd, J =
8.9, 4.5 Hz, 1H), 6.68 (dd, J = 9.2, 2.8 Hz, 1H), 5.02−4.68 (m, 2H),
4.36−4.12 (m, 2H), 3.19−2.99 (m, 2H), 2.74 (s, 3H), 2.29−2.17
(m, 1H), 1.52−1.36 (m, 1H), 1.26−1.07 (m, 2H); 13C NMR (CDCl3)
δ 157.7 (d, J = 239.6 Hz), 153.3 (s), 131.4 (d, J = 7.4 Hz), 113.7
(d, J = 23.8 Hz), 113.3 (d, J = 22.9 Hz), 112.8 (d, J = 8.5 Hz), 82.4
(d, J = 169.9 Hz), 68.5 (d, J = 19.4 Hz), 53.0 (s), 32.5 (s), 17.8
(s), 17.3 (s), 12.8 (s). HRMS (ESI) calculated for C13H18F2NO
([M + H]+), 242.1351; found, 242.1328; [α]D
20 +8.2 (c 0.1, CHCl3).
N-[[2-(5-Fluoro-2-methoxyphenyl)cyclopropyl]methyl]-
cyclopropanamine Hydrochloride (16). The title compound was
prepared from cyclopropanamine employing general method B: 1H
NMR (CDCl3) δ 9.72 (s, 2H), 6.87−6.80 (m, 1H), 6.75 (dd, J = 8.9,
4.6 Hz, 1H), 6.63 (dd, J = 9.3, 3.0 Hz, 1H), 3.83 (s, 3H), 3.20 (dd, J =
13.0, 6.9 Hz, 1H), 3.03 (dd, J = 13.0, 7.8 Hz, 1H), 2.78−2.66 (m, 1H),
2.28−2.15 (m, 1H), 1.59−1.46 (m, 1H), 1.36−1.07 (m, 4H),
0.91−0.75 (m, 2H); 13C NMR (CDCl3) δ 157.2 (d, J = 238.2 Hz),
154.4 (s), 130.9 (d, J = 7.3 Hz), 113.0 (d, J = 24.8 Hz), 112.9 (d, J =
21.2 Hz), 111.1 (d, J = 8.4 Hz), 56.1 (s), 52.2 (s), 29.5 (s), 17.8 (s),
17.0 (s), 13.5 (s), 4.1 (s), 3.8 (s); HRMS (ESI) calculated for
C14H19FNO ([M + H]
+), 236.1445; found, 236.1405.
1-Cyclopropyl-N- [ [2- (5-fluoro-2-methoxyphenyl ) -
cyclopropyl]methyl]methanamine Hydrochloride (17). The title
compound was prepared from cyclopropylmethanamine employing
general method B: 1H NMR (CDCl3) δ 9.65 (s, 2H), 6.84 (td, J = 8.5,
2.9 Hz, 1H), 6.75 (dd, J = 8.9, 4.5 Hz, 1H), 6.62 (dd, J = 9.3, 2.9 Hz,
1H), 3.84 (s, 3H), 3.26−3.01 (m, 2H), 3.00−2.88 (m, 2H), 2.23−2.09
(m, 1H), 1.56−1.40 (m, 1H), 1.39−1.22 (m, 1H), 1.19−1.07 (m, 2H),
0.76−0.64 (m, 2H), 0.55−0.40 (m, 2H); 13C NMR (CDCl3) δ 157.3
(d, J = 238.3 Hz), 154.4 (s), 130.8 (d, J = 7.4 Hz), 113.1 (d, J =
24.0 Hz), 113.0 (d, J = 24.4 Hz), 111.2 (d, J = 8.4 Hz), 56.2 (s), 51.3
(s), 50.7 (s), 17.8 (s), 17.2 (s), 13.2 (s), 7.2 (s), 4.9 (s), 4.7 (s);
HRMS (ESI) calculated for C15H21FNO ([M + H]
+), 250.1602;
found, 250.1545.
1-Cyc lohexy l -N- [ [2 - (5 -fluoro-2 -methoxypheny l ) -
cyclopropyl]methyl]methanamine Hydrochloride (18). The title
compound was prepared from cyclohexylmethylamine employing
general method B: 1H NMR (CDCl3) δ 9.52 (s, 1H), 9.43 (s, 1H),
6.88−6.80 (m, 1H), 6.76 (dd, J = 9.0, 4.6 Hz, 1H), 6.59 (dd, J = 9.3,
3.0 Hz, 1H), 3.83 (s, 3H), 3.17−3.03 (m, 2H), 2.98−2.81 (m, 2H),
2.22−2.11 (m, 1H), 2.04−1.85 (m, 3H), 1.81−1.62 (m, 3H),
1.50−1.38 (m, 1H), 1.36−1.09 (m, 5H), 1.08−0.94 (m, 2H); 13C
NMR (CDCl3) δ 157.3 (d, J = 238.3 Hz), 154.3 (s), 130.8 (d, J =
7.3 Hz), 113.0 (d, J = 22.8 Hz), 112.8 (d, J = 23.8 Hz), 111.1 (d, J =
8.4 Hz), 56.2 (s), 52.5 (s), 51. Six (s), 34.8 (s), 31.1 (s), 31.0 (s), 26.0
(s), 25.5 (s), 25.4 (s), 17.8 (s), 17.3 (s), 13.0 (s); HRMS (ESI)
calculated for C18H27FNO ([M + H]
+), 292.2071; found, 292.2073.
(+)-1-[(1S,2S)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl]-N-
(2-methoxybenzyl)methanamine Hydrochloride ((+)-19). The
title compound was prepared from 2-methoxybenzylamine employing
general method B including chiral separation: 1H NMR (CDCl3) δ
10.02 (s, 1H), 9.15 (s, 1H), 7.48 (d, J = 6.7 Hz, 1H), 7.33 (t, J =
7.8 Hz, 1H), 6.95 (t, J = 7.4 Hz, 1H), 6.88 (d, J = 8.3 Hz, 1H), 6.81
(td, J = 8.6, 2.9 Hz, 1H), 6.72 (dd, J = 8.9, 4.5 Hz, 1H), 6.59 (dd, J =
9.2, 2.9 Hz, 1H), 4.19 (m, 2H), 3.84 (s, 3H), 3.78 (s, 3H), 3.08−2.72
(m, 2H), 1.99−1.83 (m, 1H), 1.47−1.37 (m, 1H), 1.09−0.88 (m, 1H);
13C NMR (CDCl3) δ 157.9 (s), 157.2 (d, J = 238.3 Hz), 154.4 (d, J =
2.0 Hz), 132.2 (s), 131.2 (s), 130.7 (d, J = 7.4 Hz), 121.2 (s), 119.0
(s), 113.5 (d, J = 23.8 Hz), 113.1 (d, J = 22.7 Hz), 111.1 (d, J =
8.4 Hz), 110.7 (s), 56.2 (s), 55.7 (s), 50.3 (s), 45.8 (s), 17.9 (s), 17.3
(s), 13.2 (s); HRMS (ESI) calculated for C19H23FNO2 ([M + H]
+),
316.1707; found, 316.1703; [α]D
20 +34.0 (c 0.6, CHCl3).
(−)-1-[(1R,2R)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl]-N-
(2-methoxybenzyl)methanamine Hydrochloride ((−)-19). The
title compound was prepared from 2-methoxybenzylamine employing
general method B including chiral separation: 1H NMR (CDCl3) δ
10.02 (s, 1H), 9.15 (s, 1H), 7.48 (d, J = 6.7 Hz, 1H), 7.33 (t, J =
7.8 Hz, 1H), 6.95 (t, J = 7.4 Hz, 1H), 6.88 (d, J = 8.3 Hz, 1H), 6.81
(td, J = 8.6, 2.9 Hz, 1H), 6.72 (dd, J = 8.9, 4.5 Hz, 1H), 6.59 (dd, J = 9.2,
2.9 Hz, 1H), 4.19 (m, 2H), 3.84 (s, 3H), 3.78 (s, 3H), 3.07−2.72
(m, 2H), 1.99−1.83 (m, 1H), 1.47−1.37 (m, 1H), 1.09−0.87 (m, 1H);
13C NMR (CDCl3) δ 157.9 (s), 157.2 (d, J = 238.3 Hz), 154.4 (d, J =
2.0 Hz), 132.2 (s), 131.2 (s), 130.7 (d, J = 7.4 Hz), 121.2 (s), 119.0
(s), 113.5 (d, J = 23.8 Hz), 113.1 (d, J = 22.7 Hz), 111.1 (d, J =
8.4 Hz), 110.7 (s), 56.2 (s), 55.7 (s), 50.3 (s), 45.8 (s), 17.9 (s), 17.3
(s), 13.2 (s); HRMS (ESI) calculated for C19H23FNO2 ([M + H]
+),
316.1707; found, 316.1710; [α]D
20 −39.0 (c 0.2, CHCl3).
(+)-1-[(1S,2S)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl]-N-
(3-methoxybenzyl)methanamine Hydrochloride ((+)-20). The
title compound was prepared from 3-methoxybenzylamine employing
general method B including chiral separation: 1H NMR (CDCl3) δ
10.00 (s, 2H), 7.42−7.23 (m, 2H), 7.19−7.06 (m, 1H), 6.89 (d, J =
8.1 Hz, 1H), 6.82 (td, J = 8.6, 2.3 Hz, 1H), 6.73 (dd, J = 8.8, 4.4 Hz, 1H),
6.63 (dd, J = 9.1, 2.4 Hz, 1H), 4.12 (s, 2H), 3.83 (s, 3H), 3.79 (s, 3H),
3.08−2.75 (m, 2H), 2.20−2.03 (m, 1H), 1.57−1.36 (m, 1H),
1.15−0.96 (m, 2H); 13C NMR (CDCl3) δ 160.3 (s), 157.3 (d, J =
238.5 Hz), 154.4 (s), 132.0 (s), 130.7 (d, J = 7.2 Hz), 130.3 (s), 122.3
(s), 115.8 (s), 115.1 (s), 113.2 (d, J = 23.4 Hz), 113.0 (d, J = 22.2 Hz),
111.2 (d, J = 8.3 Hz), 56.2 (s), 55.7 (s), 49.9 (s, 2C), 18.0 (s), 17.0 (s),
13.4 (s); HRMS (ESI) calculated for C19H23FNO2 ([M + H]
+),
316.1707; found, 316.1706; [α]D
20 +13.6 (c 0.3, MeOH).
(−)-1-[(1R,2R)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl]-N-
(3-methoxybenzyl)methanamine Hydrochloride ((−)-20). The
title compound was prepared from 3-methoxybenzylamine employing
general method B including chiral separation: 1H NMR (CDCl3) δ
10.01 (s, 2H), 7.42−7.23 (m, 2H), 7.19−7.06 (m, 1H), 6.89 (d, J =
8.1 Hz, 1H), 6.82 (td, J = 8.6, 2.3 Hz, 1H), 6.73 (dd, J = 8.8, 4.4 Hz, 1H),
6.63 (dd, J = 9.1, 2.4 Hz, 1H), 4.12 (s, 2H), 3.83 (s, 3H), 3.79 (s, 3H),
3.08−2.75 (m, 2H), 2.20−2.03 (m, 1H), 1.57−1.36 (m, 1H),
1.15−0.96 (m, 2H); 13C NMR (CDCl3) δ 160.3 (s), 157.3 (d, J =
238.5 Hz), 154.4 (s), 132.0 (s), 130.7 (d, J = 7.2 Hz), 130.3 (s), 122.3
(s), 115.8 (s), 115.1 (s), 113.2 (d, J = 23.4 Hz), 113.0 (d, J = 22.2 Hz),
111.2 (d, J = 8.3 Hz), 56.2 (s), 55.7 (s), 49.9 (s, 2C), 18.0 (s), 17.1 (s),
13.4 (s); HRMS (ESI) calculated for C19H23FNO2 ([M + H]
+),
316.1707; found, 316.1703; [α]D
20 −15.0 (c 0.3, MeOH).
(+)-1-[(1S,2S)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl]-N-
(4-methoxybenzyl)methanamine Hydrochloride ((+)-21). The
title compound was prepared from 4-methoxybenzylamine employing
general method B including chiral separation: 1H NMR (CDCl3) δ
9.90 (s, 2H), 7.54 (d, J = 8.5 Hz, 2H), 6.90 (d, J = 8.5 Hz, 2H), 6.81
(td, J = 8.4, 3.0 Hz, 1H), 6.72 (dd, J = 8.9, 4.5 Hz, 1H), 6.62 (dd,
J = 9.3, 3.0 Hz, 1H), 4.09−4.01 (m, 2H), 3.78 (s, 3H), 3.74 (s, 3H),
3.00−2.74 (m, 2H), 2.10−2.06 (m, 1H), 1.49−1.46 (m, 1H),
1.06−1.00 (m, 2H); 13C NMR (CDCl3) δ 160.4 (s), 157.2 (d, J =
238.1 Hz), 154.3 (s), 131.9 (s, 2C), 130.8 (d, J = 7.2 Hz), 122.5 (s),
114.5 (s, 2C), 113.2 (d, J = 24.1 Hz), 112.9 (d, J = 23.0 Hz), 111.1
(d, J = 8.4 Hz), 56.1 (s), 55.3 (s), 49.6 (s), 49.3 (s), 17.9 (s), 17.0 (s),
13.4 (s); HRMS (ESI) calculated for C19H23FNO2 ([M + H]
+),
316.1707; found, 316.1700; [α]D
20 +20.6 (c 1.0, MeOH).
(−)-1-[(1R,2R)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl]-N-
(4-methoxybenzyl)methanamine Hydrochloride ((−)-21). The
title compound was prepared from 4-methoxybenzylamine employing
general method B including chiral separation: 1H NMR (CDCl3) δ
9.90 (s, 2H), 7.54 (d, J = 8.5 Hz, 2H), 6.90 (d, J = 8.5 Hz, 2H), 6.81
(td, J = 8.4, 3.0 Hz, 1H), 6.72 (dd, J = 8.9, 4.5 Hz, 1H), 6.62 (dd, J =
9.3, 3.0 Hz, 1H), 4.09−4.01 (m, 2H), 3.78 (s, 3H), 3.74 (s, 3H),
3.00−2.74 (m, 2H), 2.10−2.05 (m, 1H), 1.49−1.46 (m, 1H),
1.06−1.02 (m, 2H); 13C NMR (CDCl3) δ 160.4 (s), 157.2 (d, J =
238.1 Hz), 154.3 (s), 131.9 (s, 2C), 130.8 (d, J = 7.2 Hz), 122.5 (s),
114.5 (s, 2C), 113.2 (d, J = 24.1 Hz), 112.9 (d, J = 23.0 Hz), 111.1 (d,
J = 8.4 Hz), 56.1 (s), 55.3 (s), 49.6 (s), 49.3 (s), 17.9 (s), 17.0 (s), 13.4
(s); HRMS (ESI) calculated for C19H23FNO2 ([M + H]
+), 316.1707;
found, 316.1702; [α]D
20 −22.3 (c 1.0, MeOH).
2-[[[[2-(5-Fluoro-2-methoxyphenyl)cyclopropyl]methyl]-
amino]methyl]phenol Hydrochloride (22). The title compound
was prepared from 2-hydroxybenzylamine employing general method
B: 1H NMR (CDCl3) δ 9.52 (s, 1H), 9.07 (s, 1H), 8.75 (s, 1H),
7.27−7.10 (m, 3H), 6.88−6.75 (m, 2H), 6.69 (dd, J = 8.8, 4.3 Hz,
1H), 6.52 (dd, J = 9.1, 2.4 Hz, 1H), 4.32−4.01 (m, 2H), 3.76 (s, 3H),
3.14−2.79 (m, 2H), 2.09−1.90 (m, 1H), 1.42−1.28 (m, 1H),
1.10−0.76 (m, 2H); 13C NMR (CDCl3) δ 157.1 (d, J = 238.2 Hz),
155.8 (s), 154.4 (s), 131.5 (s), 131.4 (s), 130.3 (d, J = 7.3 Hz), 120.5
(s), 117.1 (s, 2C), 113.4 (d, J = 23.7 Hz), 113.1 (d, J = 22.3 Hz), 111.1
(d, J = 8.2 Hz), 56.2 (s), 50.7 (s), 47.5 (s), 17.8 (s), 17.4 (s), 12.7 (s);
HRMS (ESI) calculated for C18H21FNO2 ([M + H]
+), 302.1551;
found, 302.1554.
N- [ 2 - ( 2 - F l uo roe thoxy )benzy l ] - 1 - [ 2 - ( 5 -fluo ro -2 -
methoxyphenyl)cyclopropyl]methanamine Hydrochloride
(23). To a solution of the free base 22 (30 mg, 0.1 mmol),
2-fluoroethanol (10 mg, 0.15 mmol), and triphenylphosphine (52 mg,
0.2 mmol) in anhydrous THF (5 mL) at 0 °C was slowly added
diethyl azodicarboxylate (35 mg, 0.2 mmol), and the solution was then
heated in a microwave reactor at 60 °C for 45 min. The mixture was
concentrated, and the residue was purified by flash chromatography to
give the free base, which was further treated with 2 M HCl in ether to
afford the title compound as a white solid (25 mg, 63% yield): 1H
NMR (CDCl3) δ 9.86 (s, 1H), 9.23 (s, 1H), 7.58 (dd, J = 7.5, 1.4 Hz,
1H), 7.40−7.31 (m, 1H), 7.02 (t, J = 7.3 Hz, 1H), 6.91 (d, J = 8.2 Hz,
1H), 6.87−6.81 (m, 1H), 6.74 (dd, J = 8.9, 4.5 Hz, 1H), 6.61 (dd, J =
9.2, 3.0 Hz, 1H), 4.93−4.82 (m, 1H), 4.82−4.68 (m, 1H), 4.42−4.26
(m, 2H), 4.26−4.11 (m, 2H), 3.77 (s, 3H), 3.04−2.83 (m, 2H), 2.07−
1.95 (m, 1H), 1.49−1.36 (m, 1H), 1.04 (t, J = 7.1 Hz, 2H); 13C NMR
(CDCl3) δ 157.3 (d, J = 238.2 Hz), 156.8 (s), 154.4 (s), 132.6 (s),
131.3 (s), 130.8 (d, J = 7.4 Hz), 121.9 (s), 119.6 (s), 113.4 (d, J =
23.9 Hz), 113.0 (d, J = 22.7 Hz), 111.6 (s), 111.1 (d, J = 8.4 Hz), 82.0
(d, J = 170.5 Hz), 67.6 (d, J = 19.6 Hz), 56.1 (s), 50.8 (s), 45.7 (s),
17.7 (s), 17.3 (s), 13.2 (s); HRMS (ESI) calculated for C20H24F2NO2
([M + H]+), 348.1770; found, 348.1754.
2-[[[[2-(5-Fluoro-2-methoxyphenyl)cyclopropyl]methyl]-
amino]methyl]benzonitrile Hydrochloride (24). The title com-
pound was prepared from the tosylate 24b employing general method C
(K2CO3 (3.0 equiv)/CH3CN, 60 °C):
1H NMR (CDCl3) δ 14.79
(s, 1H), 9.36 (t, J = 7.8 Hz, 1H), 7.84 (m, 1H), 7.71 (t, J = 7.6 Hz, 1H),
7.63 (d, J = 7.7 Hz, 1H), 7.28 (m, 1H), 6.80 (td, J = 8.8, 2.9 Hz, 1H),
6.70 (dd, J = 8.9, 4.6 Hz, 1H), 6.58 (dd, J = 9.4, 2.9 Hz, 1H), 5.85
(s, 2H), 3.96−3.84 (m, 1H), 3.75−3.63 (m, 1H), 3.67 (s, 3H),
2.29−2.18 (m, 1H), 1.64−1.50 (m, 1H), 1.23−1.05 (m, 2H); 13C
NMR (CDCl3) δ 158.4 (s, J = 237.6 Hz), 154.5 (s), 136.5 (s), 131.4
(s, J = 7.7 Hz), 130.8 (s), 128.8 (s), 126.5 (s), 124.0 (s), 121.6 (s),
113.1 (d, J = 23.7 Hz), 112.9 (s), 112.8 (s, J = 22.9 Hz), 111.2 (d, J =
8.4 Hz), 56.2 (s), 48.3 (s), 48.2 (s), 20.4 (s), 17.4 (s), 13.3 (s); HRMS




amino]methyl]benzamide Hydrochloride (25). To a solution of
the free base 24 (35 mg, 0.1 mmol) and 5 N sodium hydroxide
(30 μL) in methanol (5 mL) was added 30% hydrogen peroxide
(0.2 mL). The mixture was heated to reflux for 1 h. The reaction
mixture was cooled, treated with water, and extracted with EtOAc. The
organic layer was washed with brine, dried over Na2SO4, and
concentrated. The residue was purified by flash chromatography to
give the free base, which was further treated with 2 M HCl in ether to
afford the title compound as a white solid (30 mg, 73% yield): 1H
NMR (CDCl3) δ 14.54 (s, 1H), 9.32 (s, 1H), 7.90−7.84 (m, 1H),
7.77−7.68 (m, 1H), 7.68−7.58 (m, 1H), 7.35−7.30 (m, 1H), 6.81
(td, J = 8.7, 2.0 Hz, 1H), 6.71 (dd, J = 8.7, 4.4 Hz, 1H), 6.59 (dd, J =
9.1, 2.1 Hz, 1H), 5.85 (s, 2H), 5.20 (s, 2H), 4.02−3.83 (m, 1H),
3.80−3.60 (m, 1H), 3.68 (s, 3H), 2.31−2.18 (m, 1H), 1.67−1.51
(m, 1H), 1.24−1.03 (m, 2H); 13C NMR (CDCl3) δ 172.5 (s), 157.2
(d, J = 238.0 Hz), 154.5 (s), 143.5 (s), 139.4 (s), 136.5 (s), 131.5
(d, J = 7.3 Hz), 130.9 (s), 128.8 (s), 121.7 (s), 113.1 (d, J = 23.8 Hz),
112.7 (d, J = 22.7 Hz), 111.2 (d, J = 8.4 Hz), 56.3 (s), 48.5 (s), 48.3
(s), 20.4 (s), 17.4 (s), 13.4 (s); HRMS (ESI) calculated for
C19H22FN2O2 ([M + H]
+), 329.1660; found, 329.1660.
(+)-N-(2-Fluorobenzyl)-1-[(1S ,2S )-(+)-2-(5-fluoro-2-
methoxyphenyl)cyclopropyl]methanamine Hydrochloride
((+)-26). The title compound was prepared from 2-fluorobenzylamine
employing general method B including chiral separation: 1H NMR
(CDCl3) δ 10.18 (s, 1H), 9.98 (s, 1H), 7.89 (t, J = 7.2 Hz, 1H), 7.37
(m, 1H), 7.21 (t, J = 7.3 Hz, 1H), 7.11 (t, J = 9.0 Hz, 1H), 6.81 (td,
J = 8.5, 3.0 Hz, 1H), 6.72 (dd, J = 8.9, 4.5 Hz, 1H), 6.63 (dd, J = 9.3,
3.0 Hz, 1H), 4.25 (s, 2H), 3.79 (s, 3H), 3.12−2.80 (m, 2H), 2.16−2.04
(m, 1H), 1.56−1.40 (m, 1H), 1.13−0.98 (m, 2H); 13C NMR (CDCl3)
δ 161.3 (d, J = 248.6 Hz), 157.2 (d, J = 238.1 Hz), 154.4 (s), 132.7 (s),
131.7 (d, J = 8.2 Hz), 130.7 (d, J = 7.3 Hz), 125.2 (d, J = 3.0 Hz),
118.0 (d, J = 14.0 Hz), 115.9 (d, J = 21.5 Hz), 113.3 (d, J = 28.5 Hz),
113.0 (d, J = 27.1 Hz), 111.1 (d, J = 8.3 Hz), 56.2 (s), 50.2 (s), 42.6
(s), 17.9 (s), 16.9 (s), 13.5 (s); HRMS (ESI) calculated for
C18H20F2NO ([M + H]
+), 304.1507; found, 304.1508; [α]D
20 +12.6
(c 0.6, MeOH).
(− ) -N - (2 -F luorobenzy l ) -1 - [ (1R , 2R ) -2 - (5 -fluoro -2 -
methoxyphenyl)cyclopropyl]methanamine Hydrochloride
((−)-26). The title compound was prepared from 2-fluorobenzylamine
employing general method B including chiral separation: 1H NMR
(CDCl3) δ 10.18 (s, 1H), 9.98 (s, 1H), 7.89 (t, J = 7.2 Hz, 1H), 7.37
(m, 1H), 7.21 (t, J = 7.3 Hz, 1H), 7.11 (t, J = 9.0 Hz, 1H), 6.81 (td, J =
8.5, 3.0 Hz, 1H), 6.72 (dd, J = 8.9, 4.5 Hz, 1H), 6.63 (dd, J = 9.3,
3.0 Hz, 1H), 4.25 (s, 2H), 3.79 (s, 3H), 3.11−2.81 (m, 2H), 2.16−2.04
(m, 1H), 1.56−1.41 (m, 1H), 1.13−0.98 (m, 2H); 13C NMR (CDCl3)
δ 161.3 (d, J = 248.6 Hz), 157.2 (d, J = 238.1 Hz), 154.4 (s), 132.7 (s),
131.7 (d, J = 8.2 Hz), 130.7 (d, J = 7.3 Hz), 125.2 (d, J = 3.0 Hz),
118.0 (d, J = 14.0 Hz), 115.9 (d, J = 21.5 Hz), 113.3 (d, J = 28.5 Hz),
113.0 (d, J = 27.1 Hz), 111.1 (d, J = 8.3 Hz), 56.2 (s), 50.2 (s), 42.6
(s), 17.9 (s), 16.9 (s), 13.5 (s); HRMS (ESI) calculated for
C18H20F2NO ([M + H]
+), 304.1507; found, 304.1508; [α]D
20 −11.7
(c 0.6, MeOH).
(+ ) -N - (2 -Ch lo robenzy l ) -1 - [ (1S , 2S ) - 2 - (5 -fluoro -2 -
methoxyphenyl)cyclopropyl]methanamine Hydrochloride
((+)-27). The title compound was prepared from 2-chlorobenzylamine
employing general method B including chiral separation: 1H NMR
(CDCl3) δ 10.25 (s, 1H), 9.84 (s, 1H), 7.97 (dd, J = 7.0, 1.8 Hz, 1H),
7.42 (dd, J = 7.0, 2.2 Hz, 1H), 7.37−7.29 (m, 2H), 6.85−6.77
(m, 1H), 6.71 (dd, J = 8.9, 4.5 Hz, 1H), 6.60 (dd, J = 9.2, 3.0 Hz, 1H),
4.35 (s, 2H), 3.76 (s, 3H), 3.10−2.90 (m, 2H), 2.14−2.02 (m, 1H),
1.55−1.39 (m, 1H), 1.08 (t, J = 7.1 Hz, 2H); 13C NMR (CDCl3) δ
157.1 (d, J = 238.2 Hz), 154.2 (s), 134.7 (s), 132.4 (s), 130.9 (s),
130.5 (d, J = 7.2 Hz), 129.9 (s), 128.8 (s), 127.8 (s), 113.2 (d, J =
24.4 Hz), 112.9 (d, J = 23.4 Hz), 111.0 (d, J = 8.3 Hz), 56.0 (s), 50.4
(s), 46.5 (s), 17.8 (s), 17.0 (s), 13.3 (s); HRMS (ESI) calculated for
C18H20ClFNO ([M + H]
+), 320.1212; found, 320.1166; [α]D
20 +4.2
(c 1.4, MeOH).
(− ) -N- (2 -Ch lorobenzy l ) -1 - [ (1R , 2R ) -2 - (5 -fluoro-2 -
methoxyphenyl)cyclopropyl]methanamine Hydrochloride
((−)-27). The title compound was prepared from 2-chlorobenzylamine
employing general method B including chiral separation: 1H NMR
(CDCl3) δ 10.25 (s, 1H), 9.84 (s, 1H), 7.97 (dd, J = 7.0, 1.8 Hz, 1H),
7.42 (dd, J = 7.0, 2.2 Hz, 1H), 7.37−7.29 (m, 2H), 6.85−6.77 (m,
1H), 6.71 (dd, J = 8.9, 4.5 Hz, 1H), 6.61 (dd, J = 9.2, 3.0 Hz, 1H),
4.35 (s, 2H), 3.76 (s, 3H), 3.11−2.90 (m, 2H), 2.14−2.02 (m, 1H),
1.55−1.39 (m, 1H), 1.07 (t, J = 7.1 Hz, 2H); 13C NMR (CDCl3) δ
157.1 (d, J = 238.2 Hz), 154.2 (s), 134.7 (s), 132.4 (s), 130.9 (s), 130.5
(d, J = 7.2 Hz), 129.9 (s), 128.8 (s), 127.8 (s), 113.2 (d, J = 24.4 Hz),
112.9 (d, J = 23.4 Hz), 111.0 (d, J = 8.3 Hz), 56.0 (s), 50.4 (s), 46.5
(s), 17.8 (s), 17.0 (s), 13.3 (s); HRMS (ESI) calculated for
C18H20ClFNO ([M + H]




ybenzyl)-N-methylmethanamine Hydrochloride (28). The title
compound was prepared from 2-methoxy-N-methylbenzylamine
employing general method B: 1H NMR (CDCl3, racemic mixture of
two pairs of enantiomeric salts) δ 11.62 (s, 1H), 11.43 (s, 1H),
7.48−7.34 (m, 4H), 7.02 (t, J = 7.5 Hz, 2H), 6.96 (d, J = 8.3 Hz, 2H),
6.91−6.82 (m, 2H), 6.77 (dd, J = 8.9, 4.5 Hz, 2H), 6.65−6.54
(m, 2H), 4.53, 4.44 (ABq, J = 12.9 Hz, 2H), 4.30, 4.22 (ABq, J =
12.9 Hz, 2H), 3.84 (s, 6H), 3.81 (s, 6H), 3.39 (dd, J = 13.3, 6.5 Hz,
1H), 3.29−3.15 (m, 2H), 3.00 (dd, J = 13.3, 7.7 Hz, 1H), 2.82 (s, 6H),
2.29−2.15 (m, 2H), 1.43−1.32 (m, 2H), 1.25−1.13 (m, 2H),
1.07−0.97 (m, 2H); 13C NMR (CDCl3) δ 158.29 (s), 158.24 (s),
157.28 (d, J = 238.3 Hz, 2C), 154.35 (s), 158.31 (s), 133.04 (s),
132.92 (s), 132.07 (s, 2C), 130.28 (d, J = 7.3 Hz, 2C), 121.36 (s, 2C),
117.26 (s, 2C), 113.22 (d, J = 22.7 Hz, 2C), 112.83 (d, J = 24.0 Hz),
112.80 (d, J = 23.9 Hz), 111.46 (s, 2C), 111.19 (d, J = 8.5 Hz, 2C),
59.43 (s), 59.23 (s), 56.00 (s, 2C), 55.52 (s, 2C), 53.81 (s), 53.43 (s),
39.34 (s), 38.82 (s), 17.98 (s), 17.74 (s), 15.95 (s), 15.90 (s), 12.90




methoxyphenyl)ethan-1-amine Hydrochloride (29). The title
compound was prepared from 1-(2-methoxyphenyl)ethylamine
employing general method B: 1H NMR (CD3OD, racemic mixture
of two pairs of enantiomers) δ 7.45 (t, J = 7.9 Hz, 2H), 7.40−7.32
(m, 2H), 7.14 (dd, J = 8.1, 3.6 Hz, 2H), 7.08 (t, J = 7.6 Hz, 2H),
6.99−6.84 (m, 4H), 6.75−6.64 (m, 2H), 4.75 (m, 2H), 3.90 (s, 3H),
3.88 (s, 3H), 3.83 (s, 3H), 3.82 (s, 3H), 3.20 (dd, J = 13.0, 5.7 Hz,
1H), 3.01 (dd, J = 13.2, 7.4 Hz, 1H), 2.92 (dd, J = 13.2, 7.4 Hz, 1H),
2.82 (dd, J = 13.0, 7.9 Hz, 1H), 2.15−2.06 (m, 2H), 1.71 (d, J =
7.0 Hz, 3H), 1.68 (d, J = 7.0 Hz, 3H), 1.34−0.91 (m, 6H); 13C NMR
(CD3OD) δ 158.61 (d, J = 237.0 Hz), 158.57 (d, J = 235.3 Hz),
158.43 (s), 158.32 (s), 155.76 (s, 2C), 132.22 (d, J = 9.7 Hz), 132.15
(s, 2C), 132.06 (d, J = 7.8 Hz), 129.76 (s, 2C), 124.97 (s), 124.90 (s),
122.56 (s), 122.52 (s), 114.05 (d, J = 19.8 Hz), 113.97 (d, J =
24.1 Hz), 113.91 (d, J = 22.7 Hz), 113.83 (d, J = 23.8 Hz), 112.71
(s, 2C), 112.44 (d, J = 8.3 Hz), 112.40 (d, J = 8.3 Hz), 56.51 (s), 56.46
(s), 56.10 (s, 2C), 55.35 (s), 55.26 (s), 51.01 (s), 50.92 (s), 18.74 (s),
18.32 (s), 18.28 (s, 2C), 18.14 (s), 18.01 (s), 13.75 (s), 13.05 (s);




methoxyphenyl)cyclopropan-1-amine Hydrochloride (30). The
title compound was prepared from 30b employing general method B:
1H NMR (CD3OD) δ 7.49−7.45 (m, 1H), 7.42 (dd, J = 7.6, 1.6 Hz,
1H), 7.13 (d, J = 8.4 Hz, 1H), 7.04 (td, J = 7.6, 0.9 Hz, 1H), 6.92−6.89
(m, 2H), 6.64 (dd, J = 8.0, 2.8 Hz, 1H), 3.97 (s, 3H), 3.86 (s, 3H),
3.02 (dd, J = 13.2, 7.3 Hz, 1H), 2.89 (dd, J = 13.1, 7.6 Hz, 1H),
2.02−1.97 (m, 1H), 1.46−1.39 (m, 1H), 1.33−0.89 (m, 4H),
1.09−1.02 (m, 1H), 0.95−0.88 (m, 1H); 13C NMR (CD3OD) δ
160.2, 159.8 (d, J = 235.5 Hz), 155.7 (d, J = 2.0 Hz), 132.8, 132.2
(d, J = 7.4 Hz), 132.0, 122.7, 122.2, 114.1 (d, J = 22.8 Hz), 113.9
(d, J = 24.2 Hz), 112.5 (d, J = 8.4 Hz), 112.4, 56.5, 56.3, 51.6, 41.6,
18.5, 18.4, 14.2, 12.4, 11.8; HRMS (ESI) calculated for C21H25FNO2
([M + H]+), 342.1864; found, 342.1833.
N-[[2-(5-Fluoro-2-methoxyphenyl)cyclopropyl]methyl]-2-(2-
methoxyphenyl)ethan-1-amine Hydrochloride (31). The title
compound was prepared from 2-(2-methoxyphenyl)ethylamine
employing general method B: 1H NMR (CDCl3) δ 9.79 (s, 1H),
9.67 (s, 1H), 7.27−7.16 (m, 2H), 6.91−6.85 (m, 1H), 6.85−6.77
(m, 2H), 6.70 (dd, J = 9.0, 4.5 Hz, 1H), 6.60 (dd, J = 9.3, 3.0 Hz, 1H),
3.75 (s, 3H), 3.71 (s, 3H), 3.42−3.21 (m, 4H), 3.21−3.02 (m, 2H),
2.19−2.09 (m, 1H), 1.53−1.40 (m, 1H), 1.18−1.07 (m, 2H); 13C
NMR (CDCl3) δ 157.5 (s), 157.2 (d, J = 238.2 Hz), 154.4 (d, J =
2.0 Hz), 130.8 (s), 130.7 (d, J = 7.2 Hz), 128.7 (s), 125.0 (s), 120.9
(s), 113.0 (d, J = 24.0 Hz), 112.9 (d, J = 24.5 Hz), 111.0 (d, J = 8.4 Hz),
110.4 (s), 56.0 (s), 55.3 (s), 51.0 (s), 46.1 (s), 27.8 (s), 17.8 (s), 17.2





The title compound was prepared from 2-thiopheneylmethylamine
employing general method B including chiral separation: 1H NMR
(CDCl3) δ 10.10 (s, 2H), 7.48 (d, J = 2.9 Hz, 1H), 7.34 (dd, J = 5.1,
1.1 Hz, 1H), 7.04 (dd, J = 5.1, 3.5 Hz, 1H), 6.86−6.79 (m, 1H), 6.74
(dd, J = 9.0, 4.6 Hz, 1H), 6.63 (dd, J = 9.3, 3.0 Hz, 1H), 4.40 (s, 2H),
3.81 (s, 3H), 3.02 (dd, J = 13.1, 7.2 Hz, 1H), 2.93 (dd, J = 13.1,
7.5 Hz, 1H), 2.19−2.09 (m, 1H), 1.55−1.42 (m, 1H), 1.13−1.02
(m, 2H); 13C NMR (CDCl3) δ 157.2 (d, J = 238.4 Hz), 154.4 (d, J =
2.0 Hz), 131.4 (s), 131.3 (s), 130.7 (d, J = 7.4 Hz), 128.0 (s), 127.9
(s), 113.3 (d, J = 22.3 Hz), 113.0 (d, J = 21.2 Hz), 111.2 (d, J =
8.3 Hz), 56.2 (s), 49.4 (s), 43.5 (s), 18.0 (s), 17.0 (s), 13.2 (s); HRMS
(ESI) calculated for C16H19FNOS ([M + H]
+), 292.1166; found,
292.1160; [α]D
20 +30.6 (c 1.0, MeOH).
(−)-1-[(1R,2R)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl]-N-
(thiophene-2-ylmethyl)methanamine Hydrochloride ((−)-32).
The title compound was prepared from 2-thiopheneylmethylamine
employing general method B including chiral separation: 1H NMR
(CDCl3) δ 10.10 (s, 2H), 7.48 (d, J = 2.9 Hz, 1H), 7.34 (dd, J = 5.1,
1.1 Hz, 1H), 7.04 (dd, J = 5.1, 3.5 Hz, 1H), 6.86−6.79 (m, 1H), 6.74
(dd, J = 9.0, 4.6 Hz, 1H), 6.63 (dd, J = 9.3, 3.0 Hz, 1H), 4.40 (s, 2H),
3.81 (s, 3H), 3.02 (dd, J = 13.1, 7.2 Hz, 1H), 2.93 (dd, J = 13.1,
7.5 Hz, 1H), 2.19−2.09 (m, 1H), 1.55−1.42 (m, 1H), 1.13−1.03
(m, 2H); 13C NMR (CDCl3) δ 157.2 (d, J = 238.4 Hz), 154.4 (d, J =
2.0 Hz), 131.4 (s), 131.3 (s), 130.7 (d, J = 7.4 Hz), 128.0 (s), 127.9
(s), 113.3 (d, J = 22.3 Hz), 113.0 (d, J = 21.2 Hz), 111.2 (d, J =
8.3 Hz), 56.2 (s), 49.5 (s), 43.5 (s), 18.0 (s), 17.0 (s), 13.2 (s); HRMS
(ESI) calculated for C16H19FNOS ([M + H]
+), 292.1166; found,
292.1160; [α]D
20 −28.5 (c 1.0, MeOH).
1-[2-(5-Fluoro-2-methoxyphenyl)cyclopropyl]-N-[(3-me-
thoxythiophene-2-yl)methyl]methanamine Hydrochloride
(33). The title compound was prepared from 3-methoxythiophene-
2-carboxaldehyde employing general method C (NaBH(OAc)3
(2.0 equiv)/DCE): 1H NMR (CD3OD) δ 7.53 (d, J = 5.6 Hz, 1H),
7.08 (d, J = 5.6 Hz, 1H), 6.95−6.90 (m, 2H), 6.75 (dd, J = 9.6, 2.4 Hz,
1H), 4.40, 4.36 (ABq, J = 14.2 Hz, 2H), 3.92 (s, 3H), 3.84 (s, 3H),
3.19 (dd, J = 13.1, 6.9 Hz, 1H), 3.05 (dd, J = 13.1, 7.9 Hz, 1H),
2.23−2.18 (m, 1H), 1.34−1.28 (m, 1H), 1.19−1.14 (m, 1H),
1.07−1.02 (m, 1H); 13C NMR (CD3OD) δ 159.5 (s), 158.6 (d, J =
236.8 Hz), 155.9 (d, J = 2.0 Hz), 132.2 (d, J = 7.5 Hz), 127.8 (s),
117.1 (s), 114.1 (d, J = 24.2 Hz), 114.0 (d, J = 22.8 Hz), 112.4 (d, J =
8.5 Hz), 108.3 (s), 59.4 (s), 56.5 (s), 51.8 (s), 42.2 (s), 18.4 (s), 18.3





(34). The title compound was prepared from 34e employing general
method B: 1H NMR (CD3OD) δ 7.60 (d, J = 3.2 Hz, 1H), 6.93−6.90
(m, 2H), 6.75 (dd, J = 9.6, 2.4 Hz, 1H), 6.61 (d, J = 3.2 Hz, 1H), 4.24,
4.19 (ABq, J = 13.6 Hz, 2H), 3.89 (s, 3H), 3.83 (s, 3H), 3.20 (dd, J =
13.1, 7.0 Hz, 1H), 3.08 (dd, J = 13.0, 7.9 Hz, 1H), 2.23−2.16 (m, 1H),
1.38−1.30 (m, 1H), 1.19−1.14 (m, 1H), 1.07−1.03 (m, 1H); 13C
NMR (CDCl3) δ 157.2 (d, J = 237.6 Hz), 156.2 (s), 154.4 (s), 130.7
(d, J = 7.4 Hz), 127.6 (s), 121.9 (s), 113.5 (d, J = 23.9 Hz), 113.1 (d,
J = 22.7 Hz), 111.1 (d, J = 8.4 Hz), 97.7 (s), 57.8 (s), 56.2 (s), 50.0 (s),
41.7 (s), 17.9 (s), 17.1 (s), 13.2 (s); HRMS (ESI) calculated for
C17H21FNO2S ([M + H]
+), 322.1272; found, 322.1241.
1-[2-(5-Fluoro-2-methoxyphenyl)cyclopropyl]-N-[(2-me-
thoxythiophene-3-yl)methyl]methanamine Hydrochloride
(35). The title compound was prepared from 35e employing general
method B: 1H NMR (CD3OD) δ 6.95−6.90 (m, 3H), 6.83 (d, J =
6.0 Hz, 1H), 6.74 (dd, J = 9.6, 2.4 Hz, 1H), 4.19, 4.14 (ABq, J =
13.5 Hz, 2H), 4.00 (s, 3H), 3.83 (s, 3H), 3.16 (dd, J = 13.0, 7.0 Hz,
1H), 3.05 (dd, J = 13.1, 7.8 Hz, 1H), 2.23−2.18 (m, 1H), 1.31−1.28
(m, 1H), 1.19−1.14 (m, 1H), 1.07−1.03 (m, 1H); 13C NMR
(CD3OD) δ 166.7 (s), 158.6 (d, J = 235.3 Hz), 155.8 (d, J = 2.0 Hz),
132.2 (d, J = 7.5 Hz), 127.3 (s), 114.0 (d, J = 23.0 Hz), 113.9 (d, J =
24.1 Hz), 113.1 (s), 112.4 (d, J = 8.5 Hz), 111.2 (s), 62.4 (s), 56.4 (s),
52.1 (s), 42.7 (s), 18.3 (s), 18.2 (s), 13.3 (s); HRMS (ESI) calculated
for C17H21FNO2S ([M + H]
+), 322.1272; found, 322.1193.
1-[2-(5-Fluoro-2-methoxyphenyl)cyclopropyl]-N-[(2-me-
thoxypyridin-3-yl)methyl]methanamine (36). The free base 36
was obtained from 2-methoxynicotinaldehyde according to the similar
procedure described for general method C (NaBH4 (1.5 equiv)/
MeOH) as a colorless oil: 1H NMR (CD3OD) δ 8.10 (dd, J = 5.0,
1.8 Hz, 1H), 7.59 (dd, J = 7.2, 1.8 Hz, 1H), 6.88 (dd, J = 7.1, 5.1 Hz,
1H), 6.86−6.78 (m, 1H), 6.75 (dd, J = 8.9, 4.6 Hz, 1H), 6.58 (dd, J =
9.5, 3.0 Hz, 1H), 3.98 (s, 3H), 3.89, 3.84 (ABq, J = 14.0 Hz, 2H), 3.81
(s, 3H), 3.08 (br s, 1H), 2.86 (dd, J = 12.1, 6.0 Hz, 1H), 2.55 (dd, J =
12.1, 7.8 Hz, 1H), 1.97−1.88 (m, 1H), 1.31−1.20 (m, 1H), 0.99−0.91
(m, 1H), 0.88−0.80 (m, 1H); 13C NMR (CD3OD) δ 162.1 (s), 157.4
(d, J = 237.6 Hz), 154.4 (s), 145.7 (s), 138.0 (s), 132.7 (d, J = 6.6 Hz),
127.2 (s), 116.9 (s), 112.7 (d, J = 23.7 Hz), 112.3 (d, J = 22.7 Hz),
111.0 (d, J = 8.6 Hz), 56.1 (s), 53.6 (s), 53.5 (s), 48.3 (s), 22.0 (s),
16.8 (s), 12.8 (s); HRMS (ESI) calculated for C18H22FN2O2 ([M +
H]+), 317.1660; found, 317.1626.
1 - ( B en zo [b ] t h i ophene - 7 - y l ) -N - [ ( 2 - ( 5 -fluo ro - 2 -
methoxyphenyl)cyclopropyl)methyl]methanamine Hydro-
chloride (37). The title compound was prepared from benzo[b]-
thiophene-7-carboxaldehyde employing general method C (NaBH-
(OAc)3 (2.0 equiv)/DCE):
1H NMR (CDCl3) δ 10.34 (s, 1H), 10.05
(s, 1H), 7.94 (d, J = 7.3 Hz, 1H), 7.84 (d, J = 7.9 Hz, 1H), 7.51−7.44
(m, 2H), 7.41 (d, J = 5.4 Hz, 1H), 6.83−6.76 (m, 1H), 6.67 (dd, J =
9.0, 4.5 Hz, 1H), 6.62 (dd, J = 9.2, 3.0 Hz, 1H), 4.46 (s, 2H), 3.64 (s,
3H), 3.12−2.94 (m, 2H), 2.08−1.97 (m, 1H), 1.53−1.42 (m, 1H),
1.15−1.01 (m, 2H); 13C NMR (CDCl3) δ 157.2 (d, J = 238.4 Hz),
154.3 (s), 140.5 (s), 140.4 (s), 130.5 (d, J = 7.3 Hz), 126.3 (s), 126.2
(s), 125.6 (s), 125.1 (s), 125.0 (s), 124.9 (s), 113.5 (d, J = 23.9 Hz),
113.1 (d, J = 22.6 Hz), 111.1 (d, J = 8.3 Hz), 56.0 (s), 50.6 (s), 48.5
(s), 18.0 (s), 17.3 (s), 13.2 (s); HRMS (ESI) calculated for
C20H21FNOS ([M + H]
+), 342.1322; found, 342.1288.
1-[2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)-N-[(1H-indol-
7-yl)methyl]methanamine Hydrochloride (38). The title com-
pound was prepared from indole-7-carboxaldehyde employing general
method C (NaBH(OAc)3 (2.0 equiv)/DCE):
1H NMR (CDCl3) δ
11.25 (s, 1H), 9.65 (s, 1H), 9.22 (s, 1H), 7.73 (dd, J = 7.4, 1.3 Hz,
1H), 7.40 (t, J = 6.9 Hz, 1H), 7.13−7.03 (m, 2H), 6.80−6.72 (m, 1H),
6.64−6.56 (m, 3H), 4.61−4.38 (m, 2H), 3.49 (s, 3H), 3.19−3.06
(m, 1H), 2.87−2.75 (m, 1H), 1.98−1.90 (m, 1H), 1.44−1.33 (m, 1H),
1.16−1.06 (m, 1H), 1.03−0.92 (m, 1H); 13C NMR (CDCl3) δ 157.2
(d, J = 238.7 Hz), 154.2 (s), 134.5 (s), 123.0 (d, J = 7.3 Hz), 129.5 (s),
126.3 (s), 124.8 (s), 123.1 (s), 119.4 (s), 113.6 (d, J = 24.1 Hz), 113.3
(d, J = 23.0 Hz), 112.8 (s), 111.1 (d, J = 8.3 Hz), 102.7 (s), 55.8 (s),
50.8 (s), 48.9 (s), 18.1 (s), 17.8 (s), 12.7 (s); HRMS (ESI) calculated
for C20H22FN2O ([M + H]
+), 325.1711; found, 325.1664.
1-[2-(5-Fluoro-2-methoxyphenyl)cyclopropyl]-N-(quinolin-8-
ylmethyl)methanamine Hydrochloride (39). The title compound
was prepared from 8-quinolinecarboxaldehyde employing general
method C (NaBH(OAc)3 (2.0 equiv)/DCE):
1H NMR (CD3OD) δ
9.01 (dd, J = 4.8, 1.5 Hz, 1H), 8.69 (d, J = 7.8 Hz, 1H), 8.27 (d, J =
7.0 Hz, 1H), 8.12 (d, J = 8.1 Hz, 1H), 7.85−7.73 (m, 2H), 6.84−6.75
(m, 1H), 6.72 (dd, J = 8.9, 4.5 Hz, 1H), 6.59 (dd, J = 9.2, 3.0 Hz, 1H),
4.96, 4.87 (ABq, J = 13.7 Hz, 2H), 3.71 (s, 3H), 3.38 (dd, J = 12.5,
7.1 Hz, 1H), 3.18−3.09 (m, 1H), 2.11−1.99 (m, 1H), 1.47−1.33 (m, 1H),
1.13−0.96 (m, 2H); 13C NMR (CD3OD) δ 158.3 (s), 157.3 (d, J =
238.5 Hz), 154.5 (s), 147.6 (s), 142.9 (s), 136.7 (s), 130.9 (s), 130.6
(d, J = 7.5 Hz), 129.3 (s), 128.9 (s), 125.5 (s), 122.3 (s), 113.6 (d, J =
24.0 Hz), 113.2 (d, J = 22.5 Hz), 111.2 (d, J = 8.4 Hz), 55.9 (s), 52.0
(s), 47.8 (s), 17.6 (s), 17.5 (s), 12.7 (s); HRMS (ESI) calculated for
C21H22FN2O ([M + H]
+), 337.1711; found, 337.1689.
(+)-1-[(1S,2S)-2-[2-(Allyloxy)-5-fluorophenyl]cyclopropyl]-N-
(2-methoxybenzyl)methanamine Hydrochloride ((+)-40). The
title compound was prepared from (+)-10 employing general method
C (NaBH4 (1.5 equiv)/MeOH):
1H NMR (CD3OD) δ 7.52−7.44
(m, 1H), 7.41 (d, J = 7.4 Hz, 1H), 7.11 (d, J = 8.3 Hz, 1H), 7.04 (t, J =
7.5 Hz, 1H), 6.98−6.83 (m, 2H), 6.74 (dd, J = 9.5, 2.8 Hz, 1H),
6.11−6.07 (m, 1H), 5.38 (dd, J = 17.3, 1.5 Hz, 1H), 5.24 (dd, J = 10.5,
1.2 Hz, 1H), 4.63−4.49 (m, 2H), 4.36, 4.26 (ABq, J = 12.9 Hz, 2H),
3.36 (s, 3H), 3.16 (d, J = 7.3 Hz, 2H), 2.39−2.21 (m, 1H), 1.50−1.34
(m, 1H), 1.25−0.99 (m, 2H); 13C NMR (CD3OD) δ 159.3 (s), 158.7
(d, J = 237.2 Hz), 154.7 (d, J = 2.1 Hz), 134.7 (s), 132.8 (s), 132.7 (s),
132.6 (d, J = 7.4 Hz), 122.0 (s), 120.5 (s), 118.0 (s), 114.1 (d, J =
8.4 Hz), 113.9 (d, J = 23.0 Hz), 113.7 (d, J = 24.2 Hz), 112.0 (s), 70.8
(s), 56.1 (s), 52.4 (s), 49.8 (s), 47.6 (s), 18.5 (s), 13.4 (s); HRMS
(ESI) calculated for C21H25FNO2 ([M + H]
+), 342.1864; found,
342.1829; [α]D
20 +10.0 (c 0.1, MeOH).
(+)-1-[(1S,2S)-2-[5-Fluoro-2-(2-fluoroethoxy)phenyl]-
cyclopropyl]-N-(2-methoxybenzyl)methanamine Hydrochlor-
ide ((+)-41). The title compound was prepared from (+)-11
employing general method C (NaBH4 (1.5 equiv)/MeOH):
1H
NMR (CD3OD) δ 7.46 (t, J = 7.9 Hz, 1H), 7.40 (d, J = 7.4 Hz, 1H),
7.11 (d, J = 8.3 Hz, 1H), 7.03 (t, J = 7.5 Hz, 1H), 6.96 (dd, J = 8.9,
4.7 Hz, 1H), 6.91 (td, J = 8.6, 2.9 Hz, 1H), 6.76 (dd, J = 9.5, 2.9 Hz,
1H), 4.85−4.61 (m, 2H), 4.36−4.21 (m, 4H), 3.89 (s, 3H), 3.20 (dd,
J = 13.1, 7.2 Hz, 1H), 3.12 (dd, J = 13.1, 7.4 Hz, 1H), 2.34−2.22
(m, 1H), 1.45−1.30 (m, 1H), 1.28−1.17 (m, 1H), 1.14−1.03 (m, 1H);
13C NMR (CD3OD) δ 159.36 (s), 158.94 (d, J = 237.6 Hz), 154.76 (d,
J = 2.1 Hz), 132.98 (d, J = 7.6 Hz), 132.71 (s), 132.70 (s), 122.03 (s),
120.44 (s), 114.26 (d, J = 8.5 Hz), 114.03 (d, J = 23.0 Hz), 113.98 (d,
J = 24.1 Hz), 112.08 (s), 83.34 (d, J = 168.4 Hz), 69.78 (d, J = 19.3 Hz),
56.12 (s), 52.28 (s), 47.58 (s), 18.56 (s), 18.42 (d, J = 1.2 Hz), 13.35
(s); HRMS (ESI) calculated for C20H24F2NO2 ([M + H]
+), 348.1770;
found, 348.1764; [α]D
20 +9.4 (c 0.5, MeOH).
Calcium Flux Assay. Calcium flux assays were performed on a
FLIPRTETRA fluorescence imaging plate reader (Molecular Dynamics)
with Flp-In-293 cells stably expressing the human 5-HT2A, 5-HT2B,
or 5-HT2C-INI receptor as previously described.
21 The cells
were preincubated in 384-well poly-L-lysine plates at a density of
10000 cells/well. The next day, the cells were loaded with Fluo-4
Direct dye (Invitrogen, 20 μL/well) for 1 h at 37 °C in drug buffer
(pH 7.4, 1× HBSS, 2.5 mM probenecid, and 20 mM HEPES).
Dilutions of each tested drug were prepared at 3× final concentration
in drug buffer (pH 7.4, 1× HBSS, 20 mM HEPES, 0.1% BSA, 0.01%
ascorbic acid). The tested drugs in 10 μL of assay buffer were added,
and calcium flux was measured every second for 5 min. For assessment
of functional selectivity, drug solutions for the FLIPR assay were
exactly the same as those used for the Tango assay (below).
Fluorescence in each well was normalized to the average of the first 10
reads (i.e., baseline fluorescence). Then the maximum fold increase
was determined, and the fold over baseline was plotted as a function of
the drug concentration. Data were normalized to 5-HT stimulation
(%) and analyzed using log [agonist] vs response in Graphpad Prism 5.0.
Tango Arrestin Recruitment Assay. The HEK cell line
expressing TEV-fused β-arrestin-2 (HTLA cells, kindly provided by
Dr. Richard Axel) and a tetracycline transactivator (tTA)-driven
luciferase were utilized for Tango assay testing β-arrestin-2 recruit-
ment.24 The HTLA cells were transfected with the 5-HT2C-INI
receptor fused to tTA containing a TEV cleavage site. The cells
were incubated as for the FLIPR assay in 40 μL except into white
384-well plates and stimulated with the same drugs used for FLIPR
(3×, 20 μL/well in HBSS, 20 mM HEPES, 0.1% BSA, 0.01% ascorbic
acid, pH 7.4). After incubation for 20 h at 37 °C and 5% CO2, the
medium containing the drugs was decanted, and 20 μL of Bright-Glo
reagent (Promega) was added per well. The plate was incubated for
20 min at room temperature for complete cell lysis before being
counted using a Wallac MicroBeta Trilux luminescence counter
(PerkinElmer). The results (relative luminescence units) were plotted
as a function of the drug concentration, normalized to the 5-HT stim-
ulation (%), and subjected to nonlinear least-squares regression
analysis using the sigmoidal dose−response function in GraphPad
Prism 5.0.
Animal Behavioral Studies. Materials and Methods. Male
C57BL/6J mice (approximately 9−10 weeks of age at the start of
testing) were obtained from Jackson Laboratories (Bar Harbor, ME).
The mice were group-housed in Tecniplast ventilated cages and were
maintained on a 12 h/12 h light/dark cycle (lights on at 7 a.m.).
The room temperature was maintained at 20−23 °C with the relative
humidity at approximately 50%. Food and water were available
ad libitum for the duration of the study, except during testing, and all
testing was conducted during the light phase of the light/dark cycle.
The behavioral tests were conducted according to established
protocols approved by the Harvard Center for Comparative Medicine
(HCCM) IACUC committee in AALAC-accredited facilities and in
accordance with the Guide for the Care and Use of Laboratory
Animals (National Institutes of Health, 2011).
Drugs. d-Amphetamine (Tocris Bioscience, Bristol, U.K.), PCP
(Sigma-Aldrich, St. Louis, MO), lorcaserin (HCl salt; Carbosynth, San
Diego, CA), and compound (+)-19 were dissolved in physiological
saline and administered by intraperitoneal (ip) injection at a concen-
tration of 10 mL/kg.
Procedures. Locomotor activity was measured in Plexiglas square
chambers (27.3 × 27.3 × 20.3 cm; Med Associates Inc., St. Albans,
VT) surrounded by infrared photobeam sources and detectors. The
mice were tested under ambient light, and data were collected by
Med Associates software (Activity Monitor, version 5.9). The mice
were injected with saline vehicle, lorcaserin (3 mg/kg), or (+)-19
(10 or 20 mg/kg), and locomotor activity was monitored for 15 min
(baseline total distance). The mice were then administered saline or
d-amphetamine (AMPH) (3 mg/kg), and the activity was measured
for an additional 90 min. In a second experiment, the mice were
administered phencyclidine (PCP) (5 mg/kg), and the activity was
measured for an additional 60 min.
Statistics. Locomotor activity was measured as the total distance
traveled (cm), assessed via infrared beam breaks. Locomotion prior to
AMPH or PCP administration (baseline, 0−15 min) was analyzed by
one-way analysis of variance (ANOVA) with drug treatment (doses of
test compounds) as the independent variable. The effect of test
compounds on AMPH- and PCP-induced hyperactivity was analyzed
by one-way ANOVA after drug treatment with AMPH (post-
amphetamine, 15−105 min) or PCP (post-PCP, 15−75 min) as the
independent variable. All significant effects were followed up with the
Student−Newman−Keuls post hoc test. An effect was considered
significant if p < 0.05 (Statview for Windows, version 5.0).
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the ACS
Publications website at DOI: 10.1021/acs.jmedchem.7b00584.
Synthetic procedures, chiral separation methods, and
characterization data of all intermediates (PDF)
Molecular formula strings and related data (CSV)
■ AUTHOR INFORMATION
Corresponding Author




Alan P. Kozikowski: 0000-0003-4795-5368
Present Address
∥J.C.: iHuman Institute, Shanghai Tech University, 99 Haike Rd.,
Pudong New District, Shanghai 201210, China.
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
Financial support from the National Institute of Mental Health
(NIMH) (Grant R01MH99993) and Psychoactive Drug
Screening Program (PDSP; Contract HHSN-271-2013-
00017-C) is gratefully acknowledged. We thank Dr. Werner
Tueckmantel for proofreading the manuscript and providing
valuable suggestions.
■ ABBREVIATIONS
5-HT, serotonin; GPCR, G-protein-coupled receptor; CNS,
central nervous system; FDA, U.S. Food and Drug Admin-
istration; ADMET, absorption, distribution, metabolism,
excretion, and toxicity; HTS, high-throughput screening;
2-PCMPA, (2-phenylcyclopropyl)methylamine; SAR, structure−
activity relationship; MW, molecular weight; HPLC, high-
performance liquid chromatography; BBB, blood−brain barrier;
FLIPR, fluorescence imaging plate reader; HEK-293, human
embryonic kidney-293 cell; CYP, cytochrome P450; AMPH,
amphetamine; PCP, phencyclidine; PPB, plasma protein
binding; hERG, human ether-a-go-go-related gene
■ REFERENCES
(1) Meltzer, H. Y.; Roth, B. L. Lorcaserin and pimavanserin:
emerging selectivity of serotonin receptor subtype-targeted drugs. J.
Clin. Invest. 2013, 123, 4986−4991.
(2) Smith, B. M.; Thomsen, W. J.; Grottick, A. J. The potential use of
selective 5-HT2C agonists in treating obesity. Expert Opin. Invest. Drugs
2006, 15, 257−266.
(3) Sargent, B. J.; Henderson, A. J. Targeting 5-HT receptors for the
treatment of obesity. Curr. Opin. Pharmacol. 2011, 11, 52−58.
(4) Rosenzweig-Lipson, S.; Comery, T. A.; Marquis, K. L.; Gross, J.;
Dunlop, J. 5-HT2C agonists as therapeutics for the treatment of
schizophrenia. Handb. Exp. Pharmacol. 2012, 213, 147−165.
(5) Berger, M.; Gray, J. A.; Roth, B. L. The expanded biology of
serotonin. Annu. Rev. Med. 2009, 60, 355−366.
(6) McCorvy, J. D.; Roth, B. L. Structure and function of serotonin G
protein-coupled receptors. Pharmacol. Ther. 2015, 150, 129−142.
(7) Wacker, D.; Wang, S.; McCorvy, J. D.; Betz, R. M.;
Venkatakrishnan, A. J.; Levit, A.; Lansu, K.; Schools, Z. L.; Che, T.;
Nichols, D. E.; Shoichet, B. K.; Dror, R. O.; Roth, B. L. Crystal
structure of an LSD-bound human serotonin receptor. Cell 2017, 168,
377−389.
(8) Rothman, R. B.; Baumann, M. H.; Savage, J. E.; Rauser, L.;
McBride, A.; Hufeisen, S. J.; Roth, B. L. Evidence for possible
involvement of 5-HT2B receptors in the cardiac valvulopathy
associated with fenfluramine and other serotonergic medications.
Circulation 2000, 102, 2836−2841.
(9) Roth, B. L. Drugs and valvular heart disease. N. Engl. J. Med.
2007, 356, 6−9.
(10) Urban, J. D.; Clarke, W. P.; von Zastrow, M.; Nichols, D. E.;
Kobilka, B.; Weinstein, H.; Javitch, J. A.; Roth, B. L.; Christopoulos, A.;
Sexton, P. M.; Miller, K. J.; Spedding, M.; Mailman, R. B. Functional
selectivity and classical concepts of quantitative pharmacology. J.
Pharmacol. Exp. Ther. 2007, 320, 1−13.
(11) DeWire, S. M.; Ahn, S.; Lefkowitz, R. J.; Shenoy, S. K. Beta-
arrestins and cell signaling. Annu. Rev. Physiol. 2007, 69, 483−510.
(12) Luttrell, L. M.; Lefkowitz, R. J. The role of beta-arrestins in the
termination and transduction of G-protein-coupled receptor signals. J.
Cell Sci. 2002, 115, 455−465.
(13) Violin, J. D.; Lefkowitz, R. J. Beta-arrestin-biased ligands at
seven-transmembrane receptors. Trends Pharmacol. Sci. 2007, 28,
416−422.
(14) Manglik, A.; Lin, H.; Aryal, D. K.; McCorvy, J. D.; Dengler, D.;
Corder, G.; Levit, A.; Kling, R. C.; Bernat, V.; Hübner, H.; Huang, X.
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